PMID-sentid Pub_year Sent_text comp_official_name comp_offset protein_name organism prot_offset 9240352-1 1997 5-(4-Chlorophenyl)-3-(1-(4-chlorobenzyl)piperidin-4-yl)pyrazole (3) was identified from screening of the Merck sample collection as a human dopamine D4 (hD4) receptor ligand with moderate affinity (61 nM) and 4-fold selectivity over human D2 (hD2) receptors. 5-(4-chlorophenyl)-3-(1-(4-chlorobenzyl)piperidin-4-yl)pyrazole 0-63 immunoglobulin heavy diversity 2-15 Homo sapiens 239-241 9240352-1 1997 5-(4-Chlorophenyl)-3-(1-(4-chlorobenzyl)piperidin-4-yl)pyrazole (3) was identified from screening of the Merck sample collection as a human dopamine D4 (hD4) receptor ligand with moderate affinity (61 nM) and 4-fold selectivity over human D2 (hD2) receptors. 5-(4-chlorophenyl)-3-(1-(4-chlorobenzyl)piperidin-4-yl)pyrazole 0-63 immunoglobulin heavy diversity 2-15 Homo sapiens 243-246 9240352-8 1997 Putting all the favorable changes together led to the discovery that 5-(4-chlorophenyl)-4-methyl-3-(1-(2-phenylethyl)piperidin-4-yl)iso xazole (36) is a nanomolar antagonist at human dopamine D4 receptors with > 500-fold selectivity over hD2 and > 200-fold selectivity over hD3. L 741742 69-142 immunoglobulin heavy diversity 2-15 Homo sapiens 241-244 7480361-4 1995 The receptors or binding sites which predominantly acted by each water extract are listed as follows: Chaihu: D2, 5-HT1A, GABA; Chuanxiong: GABA, 5-HT1A; Danggui: GABA, 5-HT1A; Danshen: BDZ; Duhuo: GABA, 5-HT1A, D2, D1; Hangqin: BDZ, D1, 5-HT1A; Qinjiao: GABA, BDZ, 5-HT1A, D2; Shengma: 5-HT1A; Suanzaoren: 5-HT1A, 5-HT2, GABA; Yangjihua: M1, 5-HT1A, 5-HT2. Water 65-70 immunoglobulin heavy diversity 2-15 Homo sapiens 274-293 8681493-1 1996 OBJECTIVES: Mazapertine is a structurally novel antipsychotic compound with high affinity for D2, D3, 5-HT1a, and alpha 1 receptors. Mazapertine 12-23 immunoglobulin heavy diversity 2-15 Homo sapiens 94-108 8867029-1 1996 Treatment with haloperidol, a dopamine receptor D-2 antagonist, for one month resulted in an increase in the mean percentage of asymmetric synapses containing a discontinuous, or perforated, postsynaptic density (PSD) [Meshul et al. Haloperidol 15-26 immunoglobulin heavy diversity 2-15 Homo sapiens 48-51 9067310-0 1997 Interactions of (+)- and (-)-8- and 7-hydroxy-2-(di-n-propylamino)tetralin at human (h)D3, hD2 and h serotonin1A receptors and their modulation of the activity of serotoninergic and dopaminergic neurones in rats. 3-azido-2,7-naphthalene disulfonate 16-24 immunoglobulin heavy diversity 2-15 Homo sapiens 91-94 9067310-0 1997 Interactions of (+)- and (-)-8- and 7-hydroxy-2-(di-n-propylamino)tetralin at human (h)D3, hD2 and h serotonin1A receptors and their modulation of the activity of serotoninergic and dopaminergic neurones in rats. (-)-8- and 7-hydroxy-2-(di-n-propylamino)tetralin 25-74 immunoglobulin heavy diversity 2-15 Homo sapiens 91-94 9067310-1 1997 The aminotetralins, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) and 7-OH-DPAT behave as preferential agonists at serotonin (5-HT)1A and dopamine D3 and D2 receptors, respectively. aminotetralins 4-18 immunoglobulin heavy diversity 2-15 Homo sapiens 159-161 9067310-1 1997 The aminotetralins, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) and 7-OH-DPAT behave as preferential agonists at serotonin (5-HT)1A and dopamine D3 and D2 receptors, respectively. 8-Hydroxy-2-(di-n-propylamino)tetralin 20-58 immunoglobulin heavy diversity 2-15 Homo sapiens 159-161 9067310-1 1997 The aminotetralins, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) and 7-OH-DPAT behave as preferential agonists at serotonin (5-HT)1A and dopamine D3 and D2 receptors, respectively. 8-Hydroxy-2-(di-n-propylamino)tetralin 60-69 immunoglobulin heavy diversity 2-15 Homo sapiens 159-161 9067310-1 1997 The aminotetralins, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) and 7-OH-DPAT behave as preferential agonists at serotonin (5-HT)1A and dopamine D3 and D2 receptors, respectively. 7-hydroxy-2-N,N-dipropylaminotetralin 75-84 immunoglobulin heavy diversity 2-15 Homo sapiens 159-161 9067310-1 1997 The aminotetralins, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) and 7-OH-DPAT behave as preferential agonists at serotonin (5-HT)1A and dopamine D3 and D2 receptors, respectively. Serotonin 120-129 immunoglobulin heavy diversity 2-15 Homo sapiens 159-161 9067310-4 1997 In binding studies, racemic 8-OH-DPAT showed 100-fold selectivity for h5-HT1A vs. hD2 and hD3 receptors and there was little difference between its (+)- and (-)-isomers either in terms of their potency at 5-HT1A receptors or of their selectivity at 5-HT1A vs hD2/hD3 sites. 8-Hydroxy-2-(di-n-propylamino)tetralin 28-37 immunoglobulin heavy diversity 2-15 Homo sapiens 82-85 9067310-4 1997 In binding studies, racemic 8-OH-DPAT showed 100-fold selectivity for h5-HT1A vs. hD2 and hD3 receptors and there was little difference between its (+)- and (-)-isomers either in terms of their potency at 5-HT1A receptors or of their selectivity at 5-HT1A vs hD2/hD3 sites. 8-Hydroxy-2-(di-n-propylamino)tetralin 28-37 immunoglobulin heavy diversity 2-15 Homo sapiens 259-262 9067310-11 1997 In contrast to 8-OH-DPAT, the (+)- and (-)isomers of 7-OH-DPAT showed marked stereoselectivity inasmuch as the latter bound with 20-fold less potency than the former at hD3 and, at higher concentrations, hD2 receptors. 7-hydroxy-2-N,N-dipropylaminotetralin 53-62 immunoglobulin heavy diversity 2-15 Homo sapiens 204-207 9067310-17 1997 In conclusion, for these substituted aminotetralins, stereospecificity is a more marked feature of interactions at hD3 (and hD2) than at h5-HT1A receptors and is more pronounced for 7- as compared to 8-OH-DPAT. aminotetralins 37-51 immunoglobulin heavy diversity 2-15 Homo sapiens 124-127 7628347-4 1995 To date, four main hypothesis have been proposed in an attempt to explain some or all for clozapine"s atypical properties: selective blockade of mesolimbic dopamine function; D1, D2, D3 and D4 receptor blockade; 5-HT2 and D2 receptor blockade; Potent alpha 1 adrenergic blockade. Clozapine 90-99 immunoglobulin heavy diversity 2-15 Homo sapiens 179-217 2167851-5 1990 In contrast, a maximum is observed with ITP and GTP; the stacking tendency of GTP following the series: GTP4- less than or equal to D(GTP)3- (K approximately 0.7 M-1) less than D(GTP)3-/D2(GTP)2- in a 1:1 ratio (K approximately 2.9 M-1) greater than D2(GTP)2- greater than D3(GTP)- (K approximately 1.5 M-1). Inosine Triphosphate 40-43 immunoglobulin heavy diversity 2-15 Homo sapiens 186-194 7915514-0 1994 [Selective dopamine D-2 autoreceptor agonists with 8-azaindole substructure: synthesis and theoretical studies]. Dopamine 11-19 immunoglobulin heavy diversity 2-15 Homo sapiens 20-23 7915514-0 1994 [Selective dopamine D-2 autoreceptor agonists with 8-azaindole substructure: synthesis and theoretical studies]. 8-azaindole 51-62 immunoglobulin heavy diversity 2-15 Homo sapiens 20-23 8289207-0 1994 Mixed 5-HT1A/D-2 activity of a new model of arylpiperazines: 1-aryl-4-[3-(1,2-dihydronaphthalen-4-yl)-n-propyl]piperazines. arylpiperazines 44-59 immunoglobulin heavy diversity 2-15 Homo sapiens 13-16 8289207-0 1994 Mixed 5-HT1A/D-2 activity of a new model of arylpiperazines: 1-aryl-4-[3-(1,2-dihydronaphthalen-4-yl)-n-propyl]piperazines. 1-aryl-4-[3-(1,2-dihydronaphthalen-4-yl)-n-propyl]piperazines 61-122 immunoglobulin heavy diversity 2-15 Homo sapiens 13-16 8328325-5 1993 Nemonapride is a highly selective dopamine D-2 antagonist, equivalent to haloperidol. Dopamine 34-42 immunoglobulin heavy diversity 2-15 Homo sapiens 43-46 1321101-1 1992 The multi-millicurie synthesis of the D-2 receptor ligand [18F](3-N-methyl)benperidol (NMB; 1-[3-(4"- [18F]fluorobenzoyl)propyl]-4-(2-keto-3-methyl-1- benzimidazolinyl)piperidine) is described. multi-millicurie 4-20 immunoglobulin heavy diversity 2-15 Homo sapiens 38-41 1321101-1 1992 The multi-millicurie synthesis of the D-2 receptor ligand [18F](3-N-methyl)benperidol (NMB; 1-[3-(4"- [18F]fluorobenzoyl)propyl]-4-(2-keto-3-methyl-1- benzimidazolinyl)piperidine) is described. [18f](3-n-methyl)benperidol 58-85 immunoglobulin heavy diversity 2-15 Homo sapiens 38-41 1321101-1 1992 The multi-millicurie synthesis of the D-2 receptor ligand [18F](3-N-methyl)benperidol (NMB; 1-[3-(4"- [18F]fluorobenzoyl)propyl]-4-(2-keto-3-methyl-1- benzimidazolinyl)piperidine) is described. nmb 87-90 immunoglobulin heavy diversity 2-15 Homo sapiens 38-41 1321101-1 1992 The multi-millicurie synthesis of the D-2 receptor ligand [18F](3-N-methyl)benperidol (NMB; 1-[3-(4"- [18F]fluorobenzoyl)propyl]-4-(2-keto-3-methyl-1- benzimidazolinyl)piperidine) is described. 1-[3-(4"- [18f]fluorobenzoyl)propyl]-4-(2-keto-3-methyl-1- benzimidazolinyl)piperidine 92-178 immunoglobulin heavy diversity 2-15 Homo sapiens 38-41 1321101-3 1992 In vitro binding assays indicated that NMB has high affinity for D-2 receptors in primate brain (K1 = 3.6 nM), with a receptor specificity exceeding that of spiperone. nmb 39-42 immunoglobulin heavy diversity 2-15 Homo sapiens 65-68 1868851-7 1991 In those cases where no other significant interaction but aromatic-ring stacking in the self-association process occurs, the release of protons from protonated nitrogen-ring sites is facilitated with increasing stacking; this holds not only for D2(GTP)2- as indicated above, but also for D2(ITP)2-, D(Ino)+, and D(Ado)+. Nitrogen 160-168 immunoglobulin heavy diversity 2-15 Homo sapiens 245-253 9620058-3 1995 We conducted a study to test the hypothesis that allelic variations of the dopamine receptors (D2, D3, D4) and the dopamine transporter (DAT) contribute to the susceptibility to PD. Dopamine 75-83 immunoglobulin heavy diversity 2-15 Homo sapiens 95-105 8032591-0 1994 Depression of high-threshold calcium currents by activation of human D2 (short) dopamine receptors expressed in differentiated NG108-15 cells. Calcium 29-36 immunoglobulin heavy diversity 2-15 Homo sapiens 69-71 8032591-12 1994 In hD2-transfected cells, but not untransfected cells, high-threshold currents were depressed by quinpirole (30 +/- 4% at 100 nM; n = 15) with a pEC50 of 8.61 +/- 0.22 (n = 5), as well as by (-)-noradrenaline (28 +/- 5% at 1 microM, n = 9). Quinpirole 97-107 immunoglobulin heavy diversity 2-15 Homo sapiens 3-6 8032591-12 1994 In hD2-transfected cells, but not untransfected cells, high-threshold currents were depressed by quinpirole (30 +/- 4% at 100 nM; n = 15) with a pEC50 of 8.61 +/- 0.22 (n = 5), as well as by (-)-noradrenaline (28 +/- 5% at 1 microM, n = 9). Norepinephrine 191-208 immunoglobulin heavy diversity 2-15 Homo sapiens 3-6 8032591-15 1994 hD2-receptor-mediated inhibition of high-threshold calcium currents was abolished by pretreatment of cells with omega-conotoxin GVIA (100 nM; n = 4). Calcium 51-58 immunoglobulin heavy diversity 2-15 Homo sapiens 0-3 8032591-15 1994 hD2-receptor-mediated inhibition of high-threshold calcium currents was abolished by pretreatment of cells with omega-conotoxin GVIA (100 nM; n = 4). gvia 128-132 immunoglobulin heavy diversity 2-15 Homo sapiens 0-3 8032591-17 1994 This current was also depressed by hD2 receptor activation (59 +/- 9% depression in 100 nM quinpirole, n = 3),and was completely blocked by nisoldipine (95 +/- 2% at 1 MicroM).6. Quinpirole 91-101 immunoglobulin heavy diversity 2-15 Homo sapiens 35-38 8032591-18 1994 These data demonstrate that activation of hD2(short) dopamine receptors can regulate both wconotoxinGVIA, and dihydropyridine-sensitive high-threshold calcium currents in neuroblastoma cells.Morever, the ability of human D2 dopamine receptors to regulate more than one type of calcium current supports the notion that these receptors have a diverse functional role in the central nervous system. 1,4-dihydropyridine 110-125 immunoglobulin heavy diversity 2-15 Homo sapiens 42-45 8032591-18 1994 These data demonstrate that activation of hD2(short) dopamine receptors can regulate both wconotoxinGVIA, and dihydropyridine-sensitive high-threshold calcium currents in neuroblastoma cells.Morever, the ability of human D2 dopamine receptors to regulate more than one type of calcium current supports the notion that these receptors have a diverse functional role in the central nervous system. 1,4-dihydropyridine 110-125 immunoglobulin heavy diversity 2-15 Homo sapiens 43-45 8032591-18 1994 These data demonstrate that activation of hD2(short) dopamine receptors can regulate both wconotoxinGVIA, and dihydropyridine-sensitive high-threshold calcium currents in neuroblastoma cells.Morever, the ability of human D2 dopamine receptors to regulate more than one type of calcium current supports the notion that these receptors have a diverse functional role in the central nervous system. Calcium 151-158 immunoglobulin heavy diversity 2-15 Homo sapiens 42-45 8032591-18 1994 These data demonstrate that activation of hD2(short) dopamine receptors can regulate both wconotoxinGVIA, and dihydropyridine-sensitive high-threshold calcium currents in neuroblastoma cells.Morever, the ability of human D2 dopamine receptors to regulate more than one type of calcium current supports the notion that these receptors have a diverse functional role in the central nervous system. Calcium 151-158 immunoglobulin heavy diversity 2-15 Homo sapiens 43-45 8032591-18 1994 These data demonstrate that activation of hD2(short) dopamine receptors can regulate both wconotoxinGVIA, and dihydropyridine-sensitive high-threshold calcium currents in neuroblastoma cells.Morever, the ability of human D2 dopamine receptors to regulate more than one type of calcium current supports the notion that these receptors have a diverse functional role in the central nervous system. Calcium 277-284 immunoglobulin heavy diversity 2-15 Homo sapiens 42-45 8032591-18 1994 These data demonstrate that activation of hD2(short) dopamine receptors can regulate both wconotoxinGVIA, and dihydropyridine-sensitive high-threshold calcium currents in neuroblastoma cells.Morever, the ability of human D2 dopamine receptors to regulate more than one type of calcium current supports the notion that these receptors have a diverse functional role in the central nervous system. Calcium 277-284 immunoglobulin heavy diversity 2-15 Homo sapiens 43-45 8104554-3 1993 The D2-like receptors, D2, D3, and D4, have approximately similar sensitivities to dopamine, but bromocriptine and raclopride are both about two orders of magnitude weaker at D4, whereas clozapine is one order more potent at D4, as compared with D2 and D3. Dopamine 83-91 immunoglobulin heavy diversity 2-15 Homo sapiens 23-29 8104554-3 1993 The D2-like receptors, D2, D3, and D4, have approximately similar sensitivities to dopamine, but bromocriptine and raclopride are both about two orders of magnitude weaker at D4, whereas clozapine is one order more potent at D4, as compared with D2 and D3. Clozapine 187-196 immunoglobulin heavy diversity 2-15 Homo sapiens 23-29 22290999-2 1993 In contrast, raclopride, a DA D-2 antagonist, produced dystonia at low doses (0.010-0.015 mg/kg). Raclopride 13-23 immunoglobulin heavy diversity 2-15 Homo sapiens 30-33 22290999-6 1993 Withdrawal of raclopride as well as NNC 756 led to behavioural D-1 and D-2 dopamine supersensitivity in the form of increased dyskinesia (including grooming after NNC 756) induced by D-1 agonist (SKF 81297) and increased arousal induced by D-2 agonist (quinpirole). Raclopride 14-24 immunoglobulin heavy diversity 2-15 Homo sapiens 71-74 22290999-6 1993 Withdrawal of raclopride as well as NNC 756 led to behavioural D-1 and D-2 dopamine supersensitivity in the form of increased dyskinesia (including grooming after NNC 756) induced by D-1 agonist (SKF 81297) and increased arousal induced by D-2 agonist (quinpirole). Raclopride 14-24 immunoglobulin heavy diversity 2-15 Homo sapiens 240-243 22290999-6 1993 Withdrawal of raclopride as well as NNC 756 led to behavioural D-1 and D-2 dopamine supersensitivity in the form of increased dyskinesia (including grooming after NNC 756) induced by D-1 agonist (SKF 81297) and increased arousal induced by D-2 agonist (quinpirole). odapipam 36-43 immunoglobulin heavy diversity 2-15 Homo sapiens 71-74 22290999-6 1993 Withdrawal of raclopride as well as NNC 756 led to behavioural D-1 and D-2 dopamine supersensitivity in the form of increased dyskinesia (including grooming after NNC 756) induced by D-1 agonist (SKF 81297) and increased arousal induced by D-2 agonist (quinpirole). odapipam 36-43 immunoglobulin heavy diversity 2-15 Homo sapiens 240-243 22290999-6 1993 Withdrawal of raclopride as well as NNC 756 led to behavioural D-1 and D-2 dopamine supersensitivity in the form of increased dyskinesia (including grooming after NNC 756) induced by D-1 agonist (SKF 81297) and increased arousal induced by D-2 agonist (quinpirole). Dopamine 75-83 immunoglobulin heavy diversity 2-15 Homo sapiens 71-74 22290999-7 1993 These results indicate that D-1 antagonists such as NNC 756 elicit fewer extrapyramidal symptoms (both acute and tardive) than D-2 antagonists such as raclopride, although extremely high doses may cause a special grooming withdrawal syndrome. Raclopride 151-161 immunoglobulin heavy diversity 2-15 Homo sapiens 127-130 1362452-2 1992 Infusion of the specific D-2 receptor agonist 2-(N-propyl-N-2-thienylethylamino)-5-hydroxytetralin ((--)-N0437) into the nigra induced a decrease in the release of dopamine in the nigra (after 1 mumol/l) as well as in the ipsilateral striatum (after 10 mumol/l). rotigotine 46-98 immunoglobulin heavy diversity 2-15 Homo sapiens 25-28 1362452-2 1992 Infusion of the specific D-2 receptor agonist 2-(N-propyl-N-2-thienylethylamino)-5-hydroxytetralin ((--)-N0437) into the nigra induced a decrease in the release of dopamine in the nigra (after 1 mumol/l) as well as in the ipsilateral striatum (after 10 mumol/l). rotigotine 100-110 immunoglobulin heavy diversity 2-15 Homo sapiens 25-28 1362452-2 1992 Infusion of the specific D-2 receptor agonist 2-(N-propyl-N-2-thienylethylamino)-5-hydroxytetralin ((--)-N0437) into the nigra induced a decrease in the release of dopamine in the nigra (after 1 mumol/l) as well as in the ipsilateral striatum (after 10 mumol/l). Dopamine 164-172 immunoglobulin heavy diversity 2-15 Homo sapiens 25-28 1362452-4 1992 Infusion of the D-2 specific receptor antagonist (--)-sulpiride into the nigra induced an increase in the release of dopamine in the nigra (after 1 mumol/l) as well as in the ipsilateral striatum (10 mumol/l). Sulpiride 49-63 immunoglobulin heavy diversity 2-15 Homo sapiens 16-19 1362452-4 1992 Infusion of the D-2 specific receptor antagonist (--)-sulpiride into the nigra induced an increase in the release of dopamine in the nigra (after 1 mumol/l) as well as in the ipsilateral striatum (10 mumol/l). Dopamine 117-125 immunoglobulin heavy diversity 2-15 Homo sapiens 16-19 1365451-1 1992 Using 32P-labelled oligonucleotides derived from the coding regions of dopamine D1, D2 and D3 receptor mRNAs we localized cells containing transcripts for these receptors in the human (hD1, hD2) and rat brain (rD1, rD2, rD3). Phosphorus-32 6-9 immunoglobulin heavy diversity 2-15 Homo sapiens 84-86 1365451-1 1992 Using 32P-labelled oligonucleotides derived from the coding regions of dopamine D1, D2 and D3 receptor mRNAs we localized cells containing transcripts for these receptors in the human (hD1, hD2) and rat brain (rD1, rD2, rD3). Phosphorus-32 6-9 immunoglobulin heavy diversity 2-15 Homo sapiens 190-193 1365451-1 1992 Using 32P-labelled oligonucleotides derived from the coding regions of dopamine D1, D2 and D3 receptor mRNAs we localized cells containing transcripts for these receptors in the human (hD1, hD2) and rat brain (rD1, rD2, rD3). Oligonucleotides 19-35 immunoglobulin heavy diversity 2-15 Homo sapiens 84-86 1686847-2 1991 We report here that multiple population spikes that characterize the burst discharge are blocked reversibly by the specific NMDA receptor antagonist, D-(-)-2-amino-5-phosphonovaleric acid (D-APV). 2-amino-4-oxo-5-phosphonopentanoic acid 189-194 immunoglobulin heavy diversity 2-15 Homo sapiens 150-157 1677765-3 1991 Clozapine has a weak binding affinity for dopamine D-1 and D-2 receptors by its slightly greater preference for D-1 receptors, as noted with a D-1:D-2 receptor binding ratio of 1.3. Clozapine 0-9 immunoglobulin heavy diversity 2-15 Homo sapiens 42-62 2167851-5 1990 In contrast, a maximum is observed with ITP and GTP; the stacking tendency of GTP following the series: GTP4- less than or equal to D(GTP)3- (K approximately 0.7 M-1) less than D(GTP)3-/D2(GTP)2- in a 1:1 ratio (K approximately 2.9 M-1) greater than D2(GTP)2- greater than D3(GTP)- (K approximately 1.5 M-1). Inosine Triphosphate 40-43 immunoglobulin heavy diversity 2-15 Homo sapiens 250-258 2167851-5 1990 In contrast, a maximum is observed with ITP and GTP; the stacking tendency of GTP following the series: GTP4- less than or equal to D(GTP)3- (K approximately 0.7 M-1) less than D(GTP)3-/D2(GTP)2- in a 1:1 ratio (K approximately 2.9 M-1) greater than D2(GTP)2- greater than D3(GTP)- (K approximately 1.5 M-1). Guanosine Triphosphate 48-51 immunoglobulin heavy diversity 2-15 Homo sapiens 186-194 2167851-5 1990 In contrast, a maximum is observed with ITP and GTP; the stacking tendency of GTP following the series: GTP4- less than or equal to D(GTP)3- (K approximately 0.7 M-1) less than D(GTP)3-/D2(GTP)2- in a 1:1 ratio (K approximately 2.9 M-1) greater than D2(GTP)2- greater than D3(GTP)- (K approximately 1.5 M-1). Guanosine Triphosphate 48-51 immunoglobulin heavy diversity 2-15 Homo sapiens 250-258 2167851-5 1990 In contrast, a maximum is observed with ITP and GTP; the stacking tendency of GTP following the series: GTP4- less than or equal to D(GTP)3- (K approximately 0.7 M-1) less than D(GTP)3-/D2(GTP)2- in a 1:1 ratio (K approximately 2.9 M-1) greater than D2(GTP)2- greater than D3(GTP)- (K approximately 1.5 M-1). Guanosine Triphosphate 78-81 immunoglobulin heavy diversity 2-15 Homo sapiens 186-194 2167851-5 1990 In contrast, a maximum is observed with ITP and GTP; the stacking tendency of GTP following the series: GTP4- less than or equal to D(GTP)3- (K approximately 0.7 M-1) less than D(GTP)3-/D2(GTP)2- in a 1:1 ratio (K approximately 2.9 M-1) greater than D2(GTP)2- greater than D3(GTP)- (K approximately 1.5 M-1). Guanosine Triphosphate 78-81 immunoglobulin heavy diversity 2-15 Homo sapiens 250-258 2167851-5 1990 In contrast, a maximum is observed with ITP and GTP; the stacking tendency of GTP following the series: GTP4- less than or equal to D(GTP)3- (K approximately 0.7 M-1) less than D(GTP)3-/D2(GTP)2- in a 1:1 ratio (K approximately 2.9 M-1) greater than D2(GTP)2- greater than D3(GTP)- (K approximately 1.5 M-1). gtp4 104-108 immunoglobulin heavy diversity 2-15 Homo sapiens 186-194 2167851-5 1990 In contrast, a maximum is observed with ITP and GTP; the stacking tendency of GTP following the series: GTP4- less than or equal to D(GTP)3- (K approximately 0.7 M-1) less than D(GTP)3-/D2(GTP)2- in a 1:1 ratio (K approximately 2.9 M-1) greater than D2(GTP)2- greater than D3(GTP)- (K approximately 1.5 M-1). gtp4 104-108 immunoglobulin heavy diversity 2-15 Homo sapiens 250-258 2167851-5 1990 In contrast, a maximum is observed with ITP and GTP; the stacking tendency of GTP following the series: GTP4- less than or equal to D(GTP)3- (K approximately 0.7 M-1) less than D(GTP)3-/D2(GTP)2- in a 1:1 ratio (K approximately 2.9 M-1) greater than D2(GTP)2- greater than D3(GTP)- (K approximately 1.5 M-1). deoxyguanosine triphosphate 132-137 immunoglobulin heavy diversity 2-15 Homo sapiens 186-194 2167851-5 1990 In contrast, a maximum is observed with ITP and GTP; the stacking tendency of GTP following the series: GTP4- less than or equal to D(GTP)3- (K approximately 0.7 M-1) less than D(GTP)3-/D2(GTP)2- in a 1:1 ratio (K approximately 2.9 M-1) greater than D2(GTP)2- greater than D3(GTP)- (K approximately 1.5 M-1). deoxyguanosine triphosphate 132-137 immunoglobulin heavy diversity 2-15 Homo sapiens 250-258 2167851-5 1990 In contrast, a maximum is observed with ITP and GTP; the stacking tendency of GTP following the series: GTP4- less than or equal to D(GTP)3- (K approximately 0.7 M-1) less than D(GTP)3-/D2(GTP)2- in a 1:1 ratio (K approximately 2.9 M-1) greater than D2(GTP)2- greater than D3(GTP)- (K approximately 1.5 M-1). d(gtp)3- 132-140 immunoglobulin heavy diversity 2-15 Homo sapiens 186-194 2167851-5 1990 In contrast, a maximum is observed with ITP and GTP; the stacking tendency of GTP following the series: GTP4- less than or equal to D(GTP)3- (K approximately 0.7 M-1) less than D(GTP)3-/D2(GTP)2- in a 1:1 ratio (K approximately 2.9 M-1) greater than D2(GTP)2- greater than D3(GTP)- (K approximately 1.5 M-1). d(gtp)3- 132-140 immunoglobulin heavy diversity 2-15 Homo sapiens 250-258 2167851-5 1990 In contrast, a maximum is observed with ITP and GTP; the stacking tendency of GTP following the series: GTP4- less than or equal to D(GTP)3- (K approximately 0.7 M-1) less than D(GTP)3-/D2(GTP)2- in a 1:1 ratio (K approximately 2.9 M-1) greater than D2(GTP)2- greater than D3(GTP)- (K approximately 1.5 M-1). Guanosine Triphosphate 78-81 immunoglobulin heavy diversity 2-15 Homo sapiens 186-194 2167851-5 1990 In contrast, a maximum is observed with ITP and GTP; the stacking tendency of GTP following the series: GTP4- less than or equal to D(GTP)3- (K approximately 0.7 M-1) less than D(GTP)3-/D2(GTP)2- in a 1:1 ratio (K approximately 2.9 M-1) greater than D2(GTP)2- greater than D3(GTP)- (K approximately 1.5 M-1). Guanosine Triphosphate 78-81 immunoglobulin heavy diversity 2-15 Homo sapiens 250-258 2167851-10 1990 However, most important is the comparison of the ITP and GTP series with previous data for ATP: ATP4- (K approximately 1.3 M-1) less than D(ATP)3- (2.1 M-1) less than 1:1 ratio of D(ATP)3-/D2(ATP)2- (6 M-1) much less than D2(ATP)2- (approximately 200 M-1) much greater than D3(ATP)- (K less than or equal to 17 M-1). Inosine Triphosphate 49-52 immunoglobulin heavy diversity 2-15 Homo sapiens 189-197 2167851-10 1990 However, most important is the comparison of the ITP and GTP series with previous data for ATP: ATP4- (K approximately 1.3 M-1) less than D(ATP)3- (2.1 M-1) less than 1:1 ratio of D(ATP)3-/D2(ATP)2- (6 M-1) much less than D2(ATP)2- (approximately 200 M-1) much greater than D3(ATP)- (K less than or equal to 17 M-1). Inosine Triphosphate 49-52 immunoglobulin heavy diversity 2-15 Homo sapiens 222-230 2167851-10 1990 However, most important is the comparison of the ITP and GTP series with previous data for ATP: ATP4- (K approximately 1.3 M-1) less than D(ATP)3- (2.1 M-1) less than 1:1 ratio of D(ATP)3-/D2(ATP)2- (6 M-1) much less than D2(ATP)2- (approximately 200 M-1) much greater than D3(ATP)- (K less than or equal to 17 M-1). Adenosine Triphosphate 91-94 immunoglobulin heavy diversity 2-15 Homo sapiens 189-197 2167851-10 1990 However, most important is the comparison of the ITP and GTP series with previous data for ATP: ATP4- (K approximately 1.3 M-1) less than D(ATP)3- (2.1 M-1) less than 1:1 ratio of D(ATP)3-/D2(ATP)2- (6 M-1) much less than D2(ATP)2- (approximately 200 M-1) much greater than D3(ATP)- (K less than or equal to 17 M-1). Adenosine Triphosphate 91-94 immunoglobulin heavy diversity 2-15 Homo sapiens 222-230 34170848-1 2021 Dopamine receptor, a polypeptide chain composed of 7 hydrophobic transmembrane regions, is a new and vital drug target, especially Dopamine receptor 2(D2). Dopamine 0-8 immunoglobulin heavy diversity 2-15 Homo sapiens 131-153 1975636-2 1990 Dopamine exerts its effects through activation of two types of receptors called D-1 and D-2. Dopamine 0-8 immunoglobulin heavy diversity 2-15 Homo sapiens 63-91 34617343-8 2021 All the included studies found that supplementation of vitamin D (D2 and D3 ), regardless of dosage, increased 25(OH)D levels compared to a placebo. Vitamin D 55-64 immunoglobulin heavy diversity 2-15 Homo sapiens 66-75 34617343-8 2021 All the included studies found that supplementation of vitamin D (D2 and D3 ), regardless of dosage, increased 25(OH)D levels compared to a placebo. 25(oh)d 111-118 immunoglobulin heavy diversity 2-15 Homo sapiens 66-75 11445186-7 2001 The addition of the "D2 like" agonist quinpirole (3 microM), but not the "D1 like" agonist SKF 38393 (10 microM), mimicked these effects. Quinpirole 38-48 immunoglobulin heavy diversity 2-15 Homo sapiens 20-23 11445186-8 2001 The "D2 like" antagonist sulpiride (10 microM), while having no effect alone, blocked the action of dopamine. Sulpiride 25-34 immunoglobulin heavy diversity 2-15 Homo sapiens 4-7 11445186-8 2001 The "D2 like" antagonist sulpiride (10 microM), while having no effect alone, blocked the action of dopamine. Dopamine 100-108 immunoglobulin heavy diversity 2-15 Homo sapiens 4-7 34571995-1 2021 Isocitrate dehydrogenase (IDH) mutations are common genetic abnormalities in glioma, which result in the accumulation of an "oncometabolite", D-2-hydroxyglutarate (D-2-HG). alpha-hydroxyglutarate 164-170 immunoglobulin heavy diversity 2-15 Homo sapiens 142-162 34994387-2 2022 Here, we hypothesize that the active metabolite D-2-hydroxyglutarate (D-2-HG) produced by the IDH-mutant enzyme leads to metabolic disruptions in surrounding cortical neurons that consequently promote seizures. alpha-hydroxyglutarate 70-76 immunoglobulin heavy diversity 2-15 Homo sapiens 48-68 35573352-2 2022 Cariprazine is a partial agonist at dopamine receptors D2 and D3 and serotonin receptor 5HT1A and an antagonist at serotonin receptors 5HT2B and 5HT2A. cariprazine 0-11 immunoglobulin heavy diversity 2-15 Homo sapiens 55-64 35573352-2 2022 Cariprazine is a partial agonist at dopamine receptors D2 and D3 and serotonin receptor 5HT1A and an antagonist at serotonin receptors 5HT2B and 5HT2A. Dopamine 36-44 immunoglobulin heavy diversity 2-15 Homo sapiens 55-64 35202123-2 2022 The first central relay of the olfactory pathway, the olfactory bulb (OB), depends, among other things, on an intact, functional crosstalk between dopaminergic interneurons and dopamine receptors (D2/D3R). Dopamine 177-185 immunoglobulin heavy diversity 2-15 Homo sapiens 197-203 2715255-0 1989 Determination of enantiomeric purity of the new D-2 dopamine agonist 2-(N-propyl-N-2-thienylethylamino)-5-hydroxytetralin (N-0437) by reversed-phase high-performance liquid chromatography after pre-column derivatization with D(+)-glucuronic acid. Dopamine 52-60 immunoglobulin heavy diversity 2-15 Homo sapiens 48-51 2527290-0 1989 Effects of D-2 antagonists on frequency-dependent stimulated dopamine overflow in nucleus accumbens and caudate-putamen. Dopamine 61-69 immunoglobulin heavy diversity 2-15 Homo sapiens 11-14 2484825-0 1989 The efficacy of the D2 and 5-HT2 antagonist risperidone (R 64,766) in the treatment of chronic psychosis. Risperidone 44-55 immunoglobulin heavy diversity 2-15 Homo sapiens 20-28 2570598-5 1989 On the other hand, the pretreatment with the D-2 agonist LY 171555 failed to induce convulsions. 4,4a,5,6,7,8,8a,9-octahydro-5-propyl-1H-pyrzolo(3,4-g)quinoline 57-66 immunoglobulin heavy diversity 2-15 Homo sapiens 45-48 2715255-0 1989 Determination of enantiomeric purity of the new D-2 dopamine agonist 2-(N-propyl-N-2-thienylethylamino)-5-hydroxytetralin (N-0437) by reversed-phase high-performance liquid chromatography after pre-column derivatization with D(+)-glucuronic acid. rotigotine 69-121 immunoglobulin heavy diversity 2-15 Homo sapiens 48-51 2715255-0 1989 Determination of enantiomeric purity of the new D-2 dopamine agonist 2-(N-propyl-N-2-thienylethylamino)-5-hydroxytetralin (N-0437) by reversed-phase high-performance liquid chromatography after pre-column derivatization with D(+)-glucuronic acid. Glucuronic Acid 225-245 immunoglobulin heavy diversity 2-15 Homo sapiens 48-51 2715255-1 1989 This paper describes an enzymic derivatization procedure that allows accurate determination of very small amounts of enantiomeric impurities in the D-2 dopamine agonist 2-(N-propyl-N-2-thienylethylamino)-5-hydroxytetralin (N-0437). rotigotine 169-221 immunoglobulin heavy diversity 2-15 Homo sapiens 148-151 2715255-1 1989 This paper describes an enzymic derivatization procedure that allows accurate determination of very small amounts of enantiomeric impurities in the D-2 dopamine agonist 2-(N-propyl-N-2-thienylethylamino)-5-hydroxytetralin (N-0437). rotigotine 223-229 immunoglobulin heavy diversity 2-15 Homo sapiens 148-151 3369858-3 1988 Esterases D-1 and D-2 were purified about 9000- and 5600-fold over the precipitates with 65% saturated ammonium sulfate in 14 and 35% yields, respectively. Ammonium Sulfate 103-119 immunoglobulin heavy diversity 2-15 Homo sapiens 0-21 2569975-6 1989 A relatively low affinity for the D-2 dopamine (DA) receptor and high affinity for the 5-HT2 receptor, producing a high 5-HT2/D-2 ratio, best distinguishes atypical antipsychotics like clozapine from typical antipsychotic drugs. Clozapine 185-194 immunoglobulin heavy diversity 2-15 Homo sapiens 34-37 2569975-6 1989 A relatively low affinity for the D-2 dopamine (DA) receptor and high affinity for the 5-HT2 receptor, producing a high 5-HT2/D-2 ratio, best distinguishes atypical antipsychotics like clozapine from typical antipsychotic drugs. Clozapine 185-194 immunoglobulin heavy diversity 2-15 Homo sapiens 126-129 3261249-0 1988 Behavioral and biochemical effect of chronic treatment with D-1 and/or D-2 dopamine agonists in MPTP monkeys. Dopamine 75-83 immunoglobulin heavy diversity 2-15 Homo sapiens 71-74 3261249-0 1988 Behavioral and biochemical effect of chronic treatment with D-1 and/or D-2 dopamine agonists in MPTP monkeys. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 96-100 immunoglobulin heavy diversity 2-15 Homo sapiens 71-74 3261249-8 1988 These results suggest that stimulation of D-1 and D-2 dopamine receptors can differently influence the mechanisms controlling dopamine agonist-induced dyskinesia in MPTP-treated monkeys. Dopamine 54-62 immunoglobulin heavy diversity 2-15 Homo sapiens 50-53 3261249-8 1988 These results suggest that stimulation of D-1 and D-2 dopamine receptors can differently influence the mechanisms controlling dopamine agonist-induced dyskinesia in MPTP-treated monkeys. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 165-169 immunoglobulin heavy diversity 2-15 Homo sapiens 50-53 3369858-4 1988 The minimum molecular weights of esterases D-1 and D-2 were estimated to be 35,000 based on the mobilities on sodium dodecyl sulfate-polyacrylamide gel electrophoresis with or without 2-mercaptoethanol. Sodium Dodecyl Sulfate 110-132 immunoglobulin heavy diversity 2-15 Homo sapiens 33-54 3369858-4 1988 The minimum molecular weights of esterases D-1 and D-2 were estimated to be 35,000 based on the mobilities on sodium dodecyl sulfate-polyacrylamide gel electrophoresis with or without 2-mercaptoethanol. polyacrylamide gels 133-151 immunoglobulin heavy diversity 2-15 Homo sapiens 33-54 3369858-4 1988 The minimum molecular weights of esterases D-1 and D-2 were estimated to be 35,000 based on the mobilities on sodium dodecyl sulfate-polyacrylamide gel electrophoresis with or without 2-mercaptoethanol. Mercaptoethanol 184-201 immunoglobulin heavy diversity 2-15 Homo sapiens 33-54 2950291-0 1987 D-2 dopamine antagonist-like effects of SCH 23390 on A9 and A10 dopamine neurons. Dopamine 4-12 immunoglobulin heavy diversity 2-15 Homo sapiens 0-3 2853885-4 1988 Niaprazine exhibits a low affinity for the vesicular monoamine transporter and for D2, alpha 2, beta, H1 and muscarinic cholinergic receptors. niaprazine 0-10 immunoglobulin heavy diversity 2-15 Homo sapiens 83-94 2961580-0 1987 The D-2 agonist quinpirole releases striatal dopamine in vivo. Quinpirole 16-26 immunoglobulin heavy diversity 2-15 Homo sapiens 4-7 2961580-0 1987 The D-2 agonist quinpirole releases striatal dopamine in vivo. Dopamine 45-53 immunoglobulin heavy diversity 2-15 Homo sapiens 4-7 2897759-2 1987 Dopamine D-1 and D-2 receptors can be labelled selectively by using 3H-SCH 23390 and 3H-Spiperone as ligands, respectively. 3h-sch 23390 68-80 immunoglobulin heavy diversity 2-15 Homo sapiens 0-20 2897759-2 1987 Dopamine D-1 and D-2 receptors can be labelled selectively by using 3H-SCH 23390 and 3H-Spiperone as ligands, respectively. UNII-8KZ649LMN4 85-97 immunoglobulin heavy diversity 2-15 Homo sapiens 0-20 2828046-3 1988 The stacking tendency follows the series, ATP4- (K = 1.3 M-1) less than D(ATP)3- (2.1 M-1) less than 1:1 ratio of D(ATP)3-/D2(ATP)-2- (6.0 M-1) much less than D2(ATP)2- (approximately 200 M-1) much greater than D3(ATP)- (K approximately less than 17 M-1) (for reasons of comparison all constants are expressed in the isodesmic model). atp4 42-46 immunoglobulin heavy diversity 2-15 Homo sapiens 159-167 2828046-3 1988 The stacking tendency follows the series, ATP4- (K = 1.3 M-1) less than D(ATP)3- (2.1 M-1) less than 1:1 ratio of D(ATP)3-/D2(ATP)-2- (6.0 M-1) much less than D2(ATP)2- (approximately 200 M-1) much greater than D3(ATP)- (K approximately less than 17 M-1) (for reasons of comparison all constants are expressed in the isodesmic model). Adenosine Triphosphate 42-45 immunoglobulin heavy diversity 2-15 Homo sapiens 159-167 2828046-3 1988 The stacking tendency follows the series, ATP4- (K = 1.3 M-1) less than D(ATP)3- (2.1 M-1) less than 1:1 ratio of D(ATP)3-/D2(ATP)-2- (6.0 M-1) much less than D2(ATP)2- (approximately 200 M-1) much greater than D3(ATP)- (K approximately less than 17 M-1) (for reasons of comparison all constants are expressed in the isodesmic model). Adenosine Triphosphate 74-77 immunoglobulin heavy diversity 2-15 Homo sapiens 159-167 2828046-3 1988 The stacking tendency follows the series, ATP4- (K = 1.3 M-1) less than D(ATP)3- (2.1 M-1) less than 1:1 ratio of D(ATP)3-/D2(ATP)-2- (6.0 M-1) much less than D2(ATP)2- (approximately 200 M-1) much greater than D3(ATP)- (K approximately less than 17 M-1) (for reasons of comparison all constants are expressed in the isodesmic model). Adenosine Triphosphate 74-77 immunoglobulin heavy diversity 2-15 Homo sapiens 159-167 2828046-3 1988 The stacking tendency follows the series, ATP4- (K = 1.3 M-1) less than D(ATP)3- (2.1 M-1) less than 1:1 ratio of D(ATP)3-/D2(ATP)-2- (6.0 M-1) much less than D2(ATP)2- (approximately 200 M-1) much greater than D3(ATP)- (K approximately less than 17 M-1) (for reasons of comparison all constants are expressed in the isodesmic model). Adenosine Triphosphate 74-77 immunoglobulin heavy diversity 2-15 Homo sapiens 159-167 2950291-0 1987 D-2 dopamine antagonist-like effects of SCH 23390 on A9 and A10 dopamine neurons. Dopamine 64-72 immunoglobulin heavy diversity 2-15 Homo sapiens 0-3 6664629-2 1983 Pharmacological characterization of the dopaminoceptors involved in this action was determined through their blockade with benzamides, selective antagonists of D-2 receptors. Benzamides 123-133 immunoglobulin heavy diversity 2-15 Homo sapiens 160-163 2907386-0 1988 [Effects of selective D-1 and D-2 dopamine antagonists on methamphetamine-induced behavioral sensitization]. Methamphetamine 58-73 immunoglobulin heavy diversity 2-15 Homo sapiens 12-33 6333810-0 1984 25-Hydroxyvitamin D and 1,25-dihydroxyvitamin D of D2 and D3 origin in maternal and umbilical cord serum after vitamin D2 supplementation in human pregnancy. 25-hydroxyvitamin D 0-19 immunoglobulin heavy diversity 2-15 Homo sapiens 51-60 6333810-0 1984 25-Hydroxyvitamin D and 1,25-dihydroxyvitamin D of D2 and D3 origin in maternal and umbilical cord serum after vitamin D2 supplementation in human pregnancy. 1,25-dihydroxyvitamin D 24-47 immunoglobulin heavy diversity 2-15 Homo sapiens 51-60 6333810-0 1984 25-Hydroxyvitamin D and 1,25-dihydroxyvitamin D of D2 and D3 origin in maternal and umbilical cord serum after vitamin D2 supplementation in human pregnancy. Ergocalciferols 111-121 immunoglobulin heavy diversity 2-15 Homo sapiens 51-60 6333810-1 1984 Serum concentrations of 25-hydroxyvitamin D (25-OHD) and 1,25-dihydroxyvitamin D [1,25-(OH)2D] of vitamin D2 and D3 origin were determined separately in 10 women before vitamin intake in early pregnancy, and repeated in maternal and cord serum obtained at delivery after 20 to 30 wk of vitamin D2 supplementation in a dose of 400 IU/day. 1,25-dihydroxyvitamin D 57-80 immunoglobulin heavy diversity 2-15 Homo sapiens 106-115 6333810-1 1984 Serum concentrations of 25-hydroxyvitamin D (25-OHD) and 1,25-dihydroxyvitamin D [1,25-(OH)2D] of vitamin D2 and D3 origin were determined separately in 10 women before vitamin intake in early pregnancy, and repeated in maternal and cord serum obtained at delivery after 20 to 30 wk of vitamin D2 supplementation in a dose of 400 IU/day. 1,25-(oh)2d 82-93 immunoglobulin heavy diversity 2-15 Homo sapiens 106-115 6333810-5 1984 The 25-OHD of D2 and D3 origin accounted for a similar proportion of the total 25-OHD in the maternal and cord serum (ratio of 25-OHD2 to 25-OHD3: 0.40 +/- 0.28 versus 0.45 +/- 0.29, p = NS), as did the respective 1,25-(OH)2D metabolites [ratio of 1,25-(OH)2D2 to 1,25-(OH)2D3: 0.73 +/- 0.35 versus 0.90 +/- 0.50, p = NS]. 25-ohd 4-10 immunoglobulin heavy diversity 2-15 Homo sapiens 14-23 6333810-5 1984 The 25-OHD of D2 and D3 origin accounted for a similar proportion of the total 25-OHD in the maternal and cord serum (ratio of 25-OHD2 to 25-OHD3: 0.40 +/- 0.28 versus 0.45 +/- 0.29, p = NS), as did the respective 1,25-(OH)2D metabolites [ratio of 1,25-(OH)2D2 to 1,25-(OH)2D3: 0.73 +/- 0.35 versus 0.90 +/- 0.50, p = NS]. 25-ohd 79-85 immunoglobulin heavy diversity 2-15 Homo sapiens 14-23 3886407-2 1985 The D-2 antagonist metoclopramide failed to block sniffing but blocked rearing and locomotion. Metoclopramide 19-33 immunoglobulin heavy diversity 2-15 Homo sapiens 4-7 6138043-0 1983 Changes in apomorphine-induced stereotypy as a result of subacute neuroleptic treatment correlates with increased D-2 receptors, but not with increases in D-1 receptors. Apomorphine 11-22 immunoglobulin heavy diversity 2-15 Homo sapiens 114-117 6138043-11 1983 In conclusion, increased apomorphine-induced stereotypy following subacute neuroleptic treatment correlates with changes in D-2 receptor numbers, but not with changes in D-1 receptors. Apomorphine 25-36 immunoglobulin heavy diversity 2-15 Homo sapiens 124-127 34024609-11 2021 Heifers that received PC had complete LBF disappearance of both D4 and D10 CL between d 2 and 4 after the first of 4 CLO treatments given 24 h apart (average 4.0 +- 0.0 and 3.2 +- 0.7 d, respectively). pc 22-24 immunoglobulin heavy diversity 2-15 Homo sapiens 86-95 18912267-0 1948 Means of support for therapeutic oxygen cylinders type D-2. Oxygen 33-39 immunoglobulin heavy diversity 2-15 Homo sapiens 55-58 7207647-0 1980 Three classes of dopamine receptor (D-2, D-3, D-4) identified by binding studies with 3H-apomorphine and 3H-domperidone. 3h-apomorphine 86-100 immunoglobulin heavy diversity 2-15 Homo sapiens 36-44 7207647-0 1980 Three classes of dopamine receptor (D-2, D-3, D-4) identified by binding studies with 3H-apomorphine and 3H-domperidone. 3h-domperidone 105-119 immunoglobulin heavy diversity 2-15 Homo sapiens 36-44 203413-0 1978 Assay of vitamins D2 and D3, and 25-hydroxyvitamins D2 and D3 in human plasma by high-performance liquid chromatography. hydroxyvitamins 36-51 immunoglobulin heavy diversity 2-15 Homo sapiens 52-61 33573681-12 2021 Lidocaine level is assessed at H4, D2, D7 and D14 to prevent local anesthetics systemic toxicity. Lidocaine 0-9 immunoglobulin heavy diversity 2-15 Homo sapiens 35-49 32995944-4 2021 Using [18F] fluspidine and [18F] fallypride PET, the purpose of this study was to assess in vivo target engagement/receptor occupancy of pridopidine to the S1R and dopamine D2/D3 receptor (D2/D3R) at clinical relevant doses in healthy volunteers (HVs) and as proof-of-concept in a small number of patients with HD. pridopidine 137-148 immunoglobulin heavy diversity 2-15 Homo sapiens 189-195 32995944-10 2021 In contrast, at 90 mg pridopidine, the D2/D3R occupancy was only minimal (~ 3%). pridopidine 22-33 immunoglobulin heavy diversity 2-15 Homo sapiens 39-45 32995944-11 2021 CONCLUSIONS: Our PET findings indicate that at clinically relevant single dose of 90 mg, pridopidine acts as a selective S1R ligand showing near to complete S1R occupancy with negligible occupancy of the D2/D3R. pridopidine 89-100 immunoglobulin heavy diversity 2-15 Homo sapiens 204-210 33995013-5 2021 Results: Compared with group R, cortisol and IL-6 levels in groups D1, D2, and D3 decreased within 24 h after the operation (T2-T6). Hydrocortisone 32-40 immunoglobulin heavy diversity 2-15 Homo sapiens 71-81 32818617-5 2020 To investigate the relationship between D2/3 BPND and mRNA expression of dopamine D2 and D3 receptors we performed [11C]-(+)-PHNO PET scans in 27 healthy subjects (12 females) and extracted D2 and D3 mRNA expression data from the AHBA. Dopamine 73-81 immunoglobulin heavy diversity 2-15 Homo sapiens 82-91 32818617-5 2020 To investigate the relationship between D2/3 BPND and mRNA expression of dopamine D2 and D3 receptors we performed [11C]-(+)-PHNO PET scans in 27 healthy subjects (12 females) and extracted D2 and D3 mRNA expression data from the AHBA. Carbon-11 116-119 immunoglobulin heavy diversity 2-15 Homo sapiens 82-91 32454148-1 2020 PURPOSE: Dopamine D2-like receptors (D2) mediate various effects of dopamine. Dopamine 9-17 immunoglobulin heavy diversity 2-15 Homo sapiens 18-35 32454148-1 2020 PURPOSE: Dopamine D2-like receptors (D2) mediate various effects of dopamine. Dopamine 9-17 immunoglobulin heavy diversity 2-15 Homo sapiens 18-20 32454148-1 2020 PURPOSE: Dopamine D2-like receptors (D2) mediate various effects of dopamine. Dopamine 68-76 immunoglobulin heavy diversity 2-15 Homo sapiens 18-35 32454148-1 2020 PURPOSE: Dopamine D2-like receptors (D2) mediate various effects of dopamine. Dopamine 68-76 immunoglobulin heavy diversity 2-15 Homo sapiens 18-20 32233111-1 2020 The adsorption of molecular deuterium (D 2 ) onto charged cobalt-fullerene-complexes Co n C 60 + ( n = 1 - 8) is measured experimentally in a few-collision reaction cell. Deuterium 28-37 immunoglobulin heavy diversity 2-15 Homo sapiens 39-42 32201327-10 2020 In summary, ICA successfully separated D2-and D3-related components of the [11C]-(+)-PHNO binding signal, establishing this approach as a powerful data-driven method to quantify distinct biological features from PET data composed of mixed data sources. Carbon-11 76-79 immunoglobulin heavy diversity 2-15 Homo sapiens 39-48 32201327-10 2020 In summary, ICA successfully separated D2-and D3-related components of the [11C]-(+)-PHNO binding signal, establishing this approach as a powerful data-driven method to quantify distinct biological features from PET data composed of mixed data sources. naxagolide 85-89 immunoglobulin heavy diversity 2-15 Homo sapiens 39-48 31010452-2 2020 Specifically, cariprazine acts as a partial agonist at the dopamine (DA) D2 and D3 receptors and serotonin 5-HT1A receptors, and as an antagonist at the 5-HT2B receptors. cariprazine 14-25 immunoglobulin heavy diversity 2-15 Homo sapiens 73-113 32233111-1 2020 The adsorption of molecular deuterium (D 2 ) onto charged cobalt-fullerene-complexes Co n C 60 + ( n = 1 - 8) is measured experimentally in a few-collision reaction cell. cobalt-fullerene 58-74 immunoglobulin heavy diversity 2-15 Homo sapiens 39-42 32233111-1 2020 The adsorption of molecular deuterium (D 2 ) onto charged cobalt-fullerene-complexes Co n C 60 + ( n = 1 - 8) is measured experimentally in a few-collision reaction cell. co n 85-89 immunoglobulin heavy diversity 2-15 Homo sapiens 39-42 31909698-1 2020 Background Isocitrate dehydrogenase (IDH) mutations are highly frequent in glioma, producing high levels of the oncometabolite D-2-hydroxyglutarate (D-2HG). alpha-hydroxyglutarate 149-154 immunoglobulin heavy diversity 2-15 Homo sapiens 127-147 32414363-1 2020 AIMS: Vitamin D measurement is a composite of vitamin D2 (25(OH)D2) and D3 (25(OH)D3) levels, and its deficiency is associated with the development of type 2 diabetes (T2DM) and diabetic complications; vitamin D deficiency may be treated with vitamin D2 supplements. Vitamin D 6-15 immunoglobulin heavy diversity 2-15 Homo sapiens 54-56 31847007-1 2020 The objective of this study (NCT01854944) was to assess D2/D3, 5-HT1A, 5-HT2A and serotonin transporter (SERT) occupancies of brexpiprazole in adult subjects with schizophrenia in order to identify the in vivo pharmacologic profile that may be relevant to the antipsychotic, antidepressant, and side effect profile of the drug. brexpiprazole 126-139 immunoglobulin heavy diversity 2-15 Homo sapiens 56-69 31092874-1 2019 D-2-Hydroxyglutarate (D-2-HG) is regarded as an oncometabolite. alpha-hydroxyglutarate 22-28 immunoglobulin heavy diversity 2-15 Homo sapiens 0-20 33211920-7 2020 A survey of pregnant women was conducted and the maternal serum total vitamin D [25 (OH) D2 and D3] level was determined by enzyme immunoassay. Vitamin D 70-79 immunoglobulin heavy diversity 2-15 Homo sapiens 89-98 31349060-5 2019 We could show that hD2HGDH is a FAD dependent protein, which is able to catalyze the oxidation of D-2HG and D-lactate to alpha-ketoglutarate and pyruvate, respectively. Lactic Acid 108-117 immunoglobulin heavy diversity 2-15 Homo sapiens 19-22 31349060-5 2019 We could show that hD2HGDH is a FAD dependent protein, which is able to catalyze the oxidation of D-2HG and D-lactate to alpha-ketoglutarate and pyruvate, respectively. Ketoglutaric Acids 121-140 immunoglobulin heavy diversity 2-15 Homo sapiens 19-22 31349060-5 2019 We could show that hD2HGDH is a FAD dependent protein, which is able to catalyze the oxidation of D-2HG and D-lactate to alpha-ketoglutarate and pyruvate, respectively. Pyruvic Acid 145-153 immunoglobulin heavy diversity 2-15 Homo sapiens 19-22 31349060-10 2019 Here, we show that hD2HGDH directly reduces recombinant human ETF, thus establishing a metabolic link between the oxidation of D-2-hydroxyglutarate and the mitochondrial electron transport chain. alpha-hydroxyglutarate 127-147 immunoglobulin heavy diversity 2-15 Homo sapiens 19-22 27241797-1 2016 In humans, the A1 (T) allele of the dopamine (DA) D2 receptor/ankyrin repeat and kinase domain containing 1 (DRD2/ANKK1) TaqIA (rs1800497) single nucleotide polymorphism has been associated with reduced striatal DA D2/D3 receptor (D2/D3R) availability. Dopamine 36-44 immunoglobulin heavy diversity 2-15 Homo sapiens 231-237 30205156-3 2019 The major circulating form of vitamin D is 25(OH)D and both D2 and D3 forms are routinely measured by LC/MS/MS to assess vitamin D status, due to their relatively long half-lives and much higher concentrations compared to 1alpha,25(OH)2D. Vitamin D 121-130 immunoglobulin heavy diversity 2-15 Homo sapiens 60-69 31089365-7 2019 The solubilization and refolding of GST-hD2 inclusion bodies was achieved with the addition of 4 M urea and subsequent dialysis to recover the fusion protein in soluble form. Urea 99-103 immunoglobulin heavy diversity 2-15 Homo sapiens 40-43 31089365-8 2019 Then the soluble GST-hD2 was purified by affinity chromatography through immobilized glutathione. Glutathione 85-96 immunoglobulin heavy diversity 2-15 Homo sapiens 21-24 31089365-10 2019 Moreover, the results of an MTT assay showed that the purified GST-hD2 has TNF-alpha neutralizing activity (Kd of 1.03 nM) and hence hD2 has the potential to be developed into a therapeutic agent. monooxyethylene trimethylolpropane tristearate 28-31 immunoglobulin heavy diversity 2-15 Homo sapiens 67-70 30006485-2 2018 These highly effective gain-of-function mutations enable mutant IDH to efficiently metabolize isocitrate to D-2-hydroxyglutarate (D 2-HG) that accumulates to high concentrations within the tumor microenvironment. isocitric acid 94-104 immunoglobulin heavy diversity 2-15 Homo sapiens 108-128 29921325-4 2018 Inhibition of Cdc42 by ML141 was realized during two phases: initiation (days -2 to 14 (D-2/14)) from undifferentiated to hepatoblast-like cells, or maturation (days 14 to 28 (D14/28)) from undifferentiated to hepatocyte-like cells. ML141 23-28 immunoglobulin heavy diversity 2-15 Homo sapiens 88-94 29921325-10 2018 The ML141(D-2/14) protocol had more pronounced effects when compared with ML141(D14/28); inhibition of DNA methylation in combination with ML141(D-2/14) showed more efficacy in rescuing the Hep-Dif of aged hADSCs. ML141 4-9 immunoglobulin heavy diversity 2-15 Homo sapiens 10-16 27540205-4 2016 Liquid chromatography tandem mass spectrometry (LC-MS/MS) was used to analyse the samples for vitamins D2 and D3 and 25-hydroxyvitamins D2 and D3 (25(OH)D2 and 25(OH)D3). 25-hydroxyvitamins 117-135 immunoglobulin heavy diversity 2-15 Homo sapiens 136-145 27244237-8 2016 SD impaired the association between striatal D2/D3R and VA-induced thalamic activation, which is essential for alertness. Vanillic Acid 56-58 immunoglobulin heavy diversity 2-15 Homo sapiens 45-51 27273047-4 2016 In our study of cannabinoid CB1/dopamine D2 interactions we sought to generate HEK293 cells expressing FLAG-tagged D2 for use in antibody-based assays of GPCR localisation and trafficking activity, however observed that stable FLAG-hD2 expression was particularly challenging to maintain. Cannabinoids 16-27 immunoglobulin heavy diversity 2-15 Homo sapiens 41-43 27273047-4 2016 In our study of cannabinoid CB1/dopamine D2 interactions we sought to generate HEK293 cells expressing FLAG-tagged D2 for use in antibody-based assays of GPCR localisation and trafficking activity, however observed that stable FLAG-hD2 expression was particularly challenging to maintain. Cannabinoids 16-27 immunoglobulin heavy diversity 2-15 Homo sapiens 115-117 27273047-4 2016 In our study of cannabinoid CB1/dopamine D2 interactions we sought to generate HEK293 cells expressing FLAG-tagged D2 for use in antibody-based assays of GPCR localisation and trafficking activity, however observed that stable FLAG-hD2 expression was particularly challenging to maintain. Dopamine 32-40 immunoglobulin heavy diversity 2-15 Homo sapiens 115-117 24992089-2 2014 Aripiprazole (APZ), a second-generation antipsychotic, manifests a novel mechanism of action by serving as a partial agonist of both D2 and serotonergic 5-HT1A receptors and antagonist of 5-HT2A receptors. Aripiprazole 14-17 immunoglobulin heavy diversity 2-15 Homo sapiens 133-159 26828302-3 2016 Furthermore, subordinate monkeys were vulnerable to cocaine self-administration, suggesting that alternations in social hierarchy can change D2/D3R availability and vulnerability to cocaine use. Cocaine 52-59 immunoglobulin heavy diversity 2-15 Homo sapiens 141-147 26828302-5 2016 Compared to controls, cocaine abusers showed lower D2/D3R availability in the caudate, putamen and ventral striatum (all p<=0.001). Cocaine 22-29 immunoglobulin heavy diversity 2-15 Homo sapiens 51-57 26828302-9 2016 However, reductions in D2/D3R availability in cocaine abusers may be driven by factors other than SES such as chronic cocaine exposure. Cocaine 46-53 immunoglobulin heavy diversity 2-15 Homo sapiens 23-29 26954979-1 2016 Neuroimaging studies have documented reduced striatal dopamine D2/D3 receptor (D2/D3R) availability in cocaine abusers, which has been associated with impaired prefrontal activity and vulnerability for relapse. Cocaine 103-110 immunoglobulin heavy diversity 2-15 Homo sapiens 79-85 26954979-5 2016 We used positron emission tomography with [(11)C]raclopride to measure striatal D2/D3R availability in 24 active cocaine abusers and 21 matched healthy controls, and interviewed them about their daily sleep patterns. Cocaine 113-120 immunoglobulin heavy diversity 2-15 Homo sapiens 80-86 26954979-10 2016 As sleep impairments are similarly observed in other types of substance abusers (for example, alcohol and methamphetamine), this mechanism may also underlie reductions in D2/D3R availability in these groups. Methamphetamine 106-121 immunoglobulin heavy diversity 2-15 Homo sapiens 171-177 26300357-3 2015 Through freely out of the barriers in the presence of soil colloids with FA added, the higher concentrations of anthracene were from 320 mug L(-1) (D1 and D3) to 390 mug L(-1) (D2 and D4) with 1 to 20 cm in length. anthracene 112-122 immunoglobulin heavy diversity 2-15 Homo sapiens 177-186 26300357-4 2015 The contents of anthracene were distributed evenly at 25 ng g(-1) dry weight (DW) (D1 and D3) and 11 ng g(-1) DW (D2 and D4) in barriers. anthracene 16-26 immunoglobulin heavy diversity 2-15 Homo sapiens 114-123 26483200-1 2015 The present study describes the optimization of a series of novel benzoxazole-piperidine (piperazine) derivatives combining high dopamine D2 and serotonin 5-HT1A, 5-HT2A receptor affinities. benzoxazole-piperidine 66-88 immunoglobulin heavy diversity 2-15 Homo sapiens 138-161 26483200-1 2015 The present study describes the optimization of a series of novel benzoxazole-piperidine (piperazine) derivatives combining high dopamine D2 and serotonin 5-HT1A, 5-HT2A receptor affinities. Piperazine 90-100 immunoglobulin heavy diversity 2-15 Homo sapiens 138-161 26368816-3 2015 The IDH1 inhibitor AGI-5198 abrogates the ability of mutant IDH1 to produce the oncometabolite D-2 hydroxyglutarate (D-2HG) in gliomas. AGI-5198 19-27 immunoglobulin heavy diversity 2-15 Homo sapiens 95-98 26156996-3 2015 Here, we addressed the role of striatal dopamine (DA) D2/D3 receptor (D2/D3R) function in chronic non-neuropathic back pain (CNBP) by comparing CNBP patients and healthy controls using PET and the D2/D3R-selective radioligand [(11)C]raclopride. Dopamine 40-48 immunoglobulin heavy diversity 2-15 Homo sapiens 70-76 26156996-3 2015 Here, we addressed the role of striatal dopamine (DA) D2/D3 receptor (D2/D3R) function in chronic non-neuropathic back pain (CNBP) by comparing CNBP patients and healthy controls using PET and the D2/D3R-selective radioligand [(11)C]raclopride. cnbp 125-129 immunoglobulin heavy diversity 2-15 Homo sapiens 70-76 25308766-0 2014 Design, synthesis and evaluation of benzo[a]thieno[3,2-g]quinolizines as novel l-SPD derivatives possessing dopamine D1, D2 and serotonin 5-HT1A multiple action profiles. benzo[a]thieno[3,2-g]quinolizines 36-69 immunoglobulin heavy diversity 2-15 Homo sapiens 121-144 25308766-0 2014 Design, synthesis and evaluation of benzo[a]thieno[3,2-g]quinolizines as novel l-SPD derivatives possessing dopamine D1, D2 and serotonin 5-HT1A multiple action profiles. stepholidine 79-84 immunoglobulin heavy diversity 2-15 Homo sapiens 121-144 26933364-1 2016 Partial agonism of D2 and 5-HT1A receptors accounts for the low incidence of extrapyramidal side-effects of aripiprazole. Aripiprazole 108-120 immunoglobulin heavy diversity 2-15 Homo sapiens 19-27 25575651-1 2015 A method for quantitative analysis of vitamin D (both D2 and D3) and its main metabolites - monohydroxylated vitamin D (25-hydroxyvitamin D2 and 25-hydroxyvitamin D3) and dihydroxylated metabolites (1,25-dihydroxyvitamin D2, 1,25-dihydroxyvitamin D3 and 24,25-dihydroxyvitamin D3) in human serum is here reported. Vitamin D 38-47 immunoglobulin heavy diversity 2-15 Homo sapiens 54-63 24947465-2 2014 In particular, it bound with high affinity (Ki < 1 nM) to human serotonin 1A (h5-HT1A)-, h5-HT2A-, long form of human D2 (hD2L)-, halpha1B-, and halpha2C-adrenergic receptors. Serotonin 67-76 immunoglobulin heavy diversity 2-15 Homo sapiens 121-123 24947465-5 2014 Brexpiprazole potently bound to rat 5-HT2A and D2 receptors in vivo, and ex vivo binding studies further confirmed high 5-HT1A receptor binding potency. brexpiprazole 0-13 immunoglobulin heavy diversity 2-15 Homo sapiens 47-49 24947465-7 2014 Furthermore, in vivo D2 partial agonist activity of brexpiprazole was confirmed by its inhibitory effect on reserpine-induced DOPA accumulation in rats. brexpiprazole 52-65 immunoglobulin heavy diversity 2-15 Homo sapiens 21-23 24947465-7 2014 Furthermore, in vivo D2 partial agonist activity of brexpiprazole was confirmed by its inhibitory effect on reserpine-induced DOPA accumulation in rats. Reserpine 108-117 immunoglobulin heavy diversity 2-15 Homo sapiens 21-23 24947465-7 2014 Furthermore, in vivo D2 partial agonist activity of brexpiprazole was confirmed by its inhibitory effect on reserpine-induced DOPA accumulation in rats. Dihydroxyphenylalanine 126-130 immunoglobulin heavy diversity 2-15 Homo sapiens 21-23 24947465-9 2014 In particular, based on a lower intrinsic activity at D2 receptors and higher binding affinities for 5-HT1A/2A receptors than aripiprazole, brexpiprazole would have a favorable antipsychotic potential without D2 receptor agonist- and antagonist-related adverse effects. brexpiprazole 140-153 immunoglobulin heavy diversity 2-15 Homo sapiens 54-56 24992089-2 2014 Aripiprazole (APZ), a second-generation antipsychotic, manifests a novel mechanism of action by serving as a partial agonist of both D2 and serotonergic 5-HT1A receptors and antagonist of 5-HT2A receptors. Aripiprazole 0-12 immunoglobulin heavy diversity 2-15 Homo sapiens 133-159 24779610-0 2014 Shuttle-cargo fusion molecules of transport peptides and the hD2/3 receptor antagonist fallypride: a feasible approach to preserve ligand-receptor binding? fallypride 87-97 immunoglobulin heavy diversity 2-15 Homo sapiens 61-64 23488743-0 2014 Synthesis and dual D2 and 5-HT1A receptor binding affinities of 5-piperidinyl and 5-piperazinyl-1H-benzo[d]imidazol-2(3H)-ones. 5-piperidinyl and 5-piperazinyl-1h-benzo[d]imidazol-2(3h)-ones 64-126 immunoglobulin heavy diversity 2-15 Homo sapiens 19-27 23488743-1 2014 A series of new 5-piperidinyl and 5-piperazinyl-1H-benzo[d]imidazol-2(3H)-ones have been synthesized and evaluated for dual D2 and 5-HT1A receptor binding affinities. 5-piperidinyl and 5-piperazinyl-1h-benzo[d]imidazol-2(3h)-ones 16-78 immunoglobulin heavy diversity 2-15 Homo sapiens 124-132 23488743-7 2014 The structure-activity relationship studies showed that cyclopentenylpyridine and cyclopentenylbenzyl groups contribute significantly to the dual D2 and 5-HT1A receptor binding affinities of these compounds. cyclopentenylpyridine 56-77 immunoglobulin heavy diversity 2-15 Homo sapiens 146-154 23488743-7 2014 The structure-activity relationship studies showed that cyclopentenylpyridine and cyclopentenylbenzyl groups contribute significantly to the dual D2 and 5-HT1A receptor binding affinities of these compounds. cyclopentenylbenzyl 82-101 immunoglobulin heavy diversity 2-15 Homo sapiens 146-154 24513908-3 2014 They are of the general structure cyclo(Boc-Cys-Pro-X-Cys-OMe) with the amino acid X being either glycine (1), or L- or D-leucine (L- or D-2). emodepside 34-39 immunoglobulin heavy diversity 2-15 Homo sapiens 137-140 24513908-3 2014 They are of the general structure cyclo(Boc-Cys-Pro-X-Cys-OMe) with the amino acid X being either glycine (1), or L- or D-leucine (L- or D-2). boc-cys-pro-x-cys-ome 40-61 immunoglobulin heavy diversity 2-15 Homo sapiens 137-140 24024527-0 2014 Synthesis and dual D2 and 5-HT1A receptor binding affinities of 7-piperazinyl and 7-piperidinyl-3,4-dihydroquinazolin-2(1H)-ones. 7-piperazinyl 64-77 immunoglobulin heavy diversity 2-15 Homo sapiens 19-27 24024527-0 2014 Synthesis and dual D2 and 5-HT1A receptor binding affinities of 7-piperazinyl and 7-piperidinyl-3,4-dihydroquinazolin-2(1H)-ones. 7-piperidinyl-3,4-dihydroquinazolin-2(1h)-ones 82-128 immunoglobulin heavy diversity 2-15 Homo sapiens 19-27 24024527-7 2014 The structure-activity relationship studies revealed that cyclopentenylpyridine and cyclopentenylbenzyl groups contribute significantly to the dual D2 and 5-HT1A receptor binding affinities of these compounds. cyclopentenylpyridine 58-79 immunoglobulin heavy diversity 2-15 Homo sapiens 148-156 24024527-7 2014 The structure-activity relationship studies revealed that cyclopentenylpyridine and cyclopentenylbenzyl groups contribute significantly to the dual D2 and 5-HT1A receptor binding affinities of these compounds. cyclopentenylbenzyl 84-103 immunoglobulin heavy diversity 2-15 Homo sapiens 148-156 23147569-8 2013 Based on proliferating cell nuclear antigen (PCNA) staining and expression of cyclins D1, D2, E, and A, vorinostat seems to impair proliferation by down-regulating the expression of these proteins. Vorinostat 104-114 immunoglobulin heavy diversity 2-15 Homo sapiens 78-95 23720609-0 2013 Accelerated habit formation following amphetamine exposure is reversed by D1, but enhanced by D2, receptor antagonists. Amphetamine 38-49 immunoglobulin heavy diversity 2-15 Homo sapiens 94-106 23168298-7 2013 After 25 weeks, participants randomised to D2 and placebo had a significant reduction in serum 25(OH)D3 concentrations over the winter months compared with vitamin D3-supplemented participants (both P< 0.001). (oh)d3 97-103 immunoglobulin heavy diversity 2-15 Homo sapiens 43-45 23086645-8 2012 The characteristic ladder of apoptosis in DNA electrophoresis was detected in MCF-7 cells treated with 10.0 mumol/L polysaccharide of snakegourd root at d 2. Polysaccharides 116-130 immunoglobulin heavy diversity 2-15 Homo sapiens 153-156 22001575-3 2011 In the present study, the gene expression levels of dopamine receptor (D2, D3), inward rectified potassium channels subunits Kir2 (Kir2.1, Kir2.2, Kir2.3, Kir2.4) and ATP-sensitive potassium channel subunit Kir6.2 in PBLs were analyzed using quantitative real-time PCR among 20 PD patients with medication, 10 PD patients without medication and 16 healthy controls, respectively. Dopamine 52-60 immunoglobulin heavy diversity 2-15 Homo sapiens 71-77 20641188-8 2004 In binding studies, (123)I-labeled epidepride, an analog of isoremoxipride, was found to have high potency and low nonspecific binding, and to be selective for striatal and extrastriatal D2 receptors (9). FLB 457 60-74 immunoglobulin heavy diversity 2-15 Homo sapiens 187-189 20641188-11 2004 (S)-N-(1-Ethyl-2-pyrrolidinyl)methyl)-5-bromo-2,3-dimethoxybenzamide (FLB 457, or isoremoxipride) had very high affinity for D2 (Ki = 0.017 nM) and D3 (Ki = 0.022 nM) receptors but not other neurotransmitter receptors (14). UNII-8PK3XYY6EX 0-68 immunoglobulin heavy diversity 2-15 Homo sapiens 125-127 20641188-11 2004 (S)-N-(1-Ethyl-2-pyrrolidinyl)methyl)-5-bromo-2,3-dimethoxybenzamide (FLB 457, or isoremoxipride) had very high affinity for D2 (Ki = 0.017 nM) and D3 (Ki = 0.022 nM) receptors but not other neurotransmitter receptors (14). FLB 457 82-96 immunoglobulin heavy diversity 2-15 Homo sapiens 125-127 20161135-3 2009 A modified synthetic route to combretastatin D-2 (5) was devised in order to further evaluate its biological activity, for its conversion to phosphate prodrugs (25-28), and as a route to obtaining dihydro-combretastatin D-2 (42). Phosphates 141-150 immunoglobulin heavy diversity 2-15 Homo sapiens 45-48 20641398-13 2004 In binding studies, [(123)I]-labeled epidepride, an analog of isoremoxipride, was found to have high potency and low nonspecific binding, and to be selective for striatal and extrastriatal D2 receptors (9). FLB 457 62-76 immunoglobulin heavy diversity 2-15 Homo sapiens 189-191 20641398-17 2004 (-)-N-Propyl-norapomorphine (NPA), a full dopamine D2/3 receptor agonist, was reported to have the Khigh and Klow values of 0.07-0.4 and 20-200 nM for D2 receptors, respectively (5, 14-16). N-n-propylnorapomorphine 0-27 immunoglobulin heavy diversity 2-15 Homo sapiens 51-53 20641398-17 2004 (-)-N-Propyl-norapomorphine (NPA), a full dopamine D2/3 receptor agonist, was reported to have the Khigh and Klow values of 0.07-0.4 and 20-200 nM for D2 receptors, respectively (5, 14-16). N-n-propylnorapomorphine 29-32 immunoglobulin heavy diversity 2-15 Homo sapiens 51-53 21421726-0 2011 Contribution of SPECT measurements of D2 and 5-HT2A occupancy to the clinical development of the antipsychotic SB-773812. SB-737050-A 111-120 immunoglobulin heavy diversity 2-15 Homo sapiens 38-46 21177785-1 2011 BACKGROUND: Current unitage for the calciferols suggests that equimolar quantities of vitamins D(2) (D2) and D(3) (D3) are biologically equivalent. Ergocalciferols 36-47 immunoglobulin heavy diversity 2-15 Homo sapiens 101-103 20302892-2 2010 As anticipated, dopamine bound with high affinity to D1 (IC(50) 1.1 + or - 0.16 microM) and D2 (IC(50) 0.7 + or - 0.3 microM) dopamine receptors. Dopamine 16-24 immunoglobulin heavy diversity 2-15 Homo sapiens 92-106 20161135-4 2009 A parallel first total synthesis of dihydro-combretastatin D-2 was completed, proceeding from a saturated 3-phenylpropionic ester intermediate via the Ullmann biaryl ether reaction (39-41). dihydro-combretastatin 36-58 immunoglobulin heavy diversity 2-15 Homo sapiens 59-62 20161135-4 2009 A parallel first total synthesis of dihydro-combretastatin D-2 was completed, proceeding from a saturated 3-phenylpropionic ester intermediate via the Ullmann biaryl ether reaction (39-41). 3-phenylpropionic ester 106-129 immunoglobulin heavy diversity 2-15 Homo sapiens 59-62 19166896-1 2009 We examined the efficacy and tolerability of perospirone, a dopamine D2 and 5-HT2A receptor antagonist and a partial 5-HT1A receptor agonist, in the augmentation of antidepressant treatment of partially responding and nonresponding patients with major depressive disorder. perospirone 45-56 immunoglobulin heavy diversity 2-15 Homo sapiens 69-77 19091563-4 2009 Amide, amine and ester elements have been used generally to maintain or slightly shift affinity at dopamine D(2)-like receptors (D2 and D3), to decrease affinity at histamine H(1) receptors, and to obtain H3R ligands with low nanomolar or subnanomolar affinity. Amides 0-5 immunoglobulin heavy diversity 2-15 Homo sapiens 129-138 19245230-5 2009 In reactions of O(2) with d(0) 1 and 2, oxidation of the ligands is the prevailing pathway. Oxygen 16-20 immunoglobulin heavy diversity 2-15 Homo sapiens 26-38 19091563-4 2009 Amide, amine and ester elements have been used generally to maintain or slightly shift affinity at dopamine D(2)-like receptors (D2 and D3), to decrease affinity at histamine H(1) receptors, and to obtain H3R ligands with low nanomolar or subnanomolar affinity. Amines 7-12 immunoglobulin heavy diversity 2-15 Homo sapiens 129-138 19091563-4 2009 Amide, amine and ester elements have been used generally to maintain or slightly shift affinity at dopamine D(2)-like receptors (D2 and D3), to decrease affinity at histamine H(1) receptors, and to obtain H3R ligands with low nanomolar or subnanomolar affinity. Esters 17-22 immunoglobulin heavy diversity 2-15 Homo sapiens 129-138 18812476-7 2008 Placebo-adjusted fasting plasma glucose decreased by -26.7 and -50.7 mg/dl [95% confidence interval (-46.3, -7.06) and (-75.4, -26.0)] on d 2 and 9, respectively. Glucose 32-39 immunoglobulin heavy diversity 2-15 Homo sapiens 138-147 17579404-6 2007 The helical polyacetylene synthesized in the N*-LC containing D-2 exhibited highly screwed fibrils, but not a bundle of fibrils. Polyacetylene Polymer 12-25 immunoglobulin heavy diversity 2-15 Homo sapiens 62-65 18690117-9 2008 Although these results are preliminary, this study is the first to suggest that genetic polymorphisms related to function in the dopamine D4, and perhaps D2, receptor may modulate initial sensitivity to nicotine before the onset of dependence and may do so differentially between men and women. Nicotine 203-211 immunoglobulin heavy diversity 2-15 Homo sapiens 154-166 17579404-6 2007 The helical polyacetylene synthesized in the N*-LC containing D-2 exhibited highly screwed fibrils, but not a bundle of fibrils. n*-lc 45-50 immunoglobulin heavy diversity 2-15 Homo sapiens 62-65 16020493-1 2005 BACKGROUND: Measurement of 25-hydroxyvitamin D2 and D3 (25-OH D2 and D3) is essential for investigating vitamin D deficiency. Vitamin D 37-46 immunoglobulin heavy diversity 2-15 Homo sapiens 62-71 17375087-0 2007 F15063, a potential antipsychotic with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. N-((2,2-dimethyl-2,3-dihydrobenzofuran-7-yloxy)ethyl)-3-(cyclopent-1-enyl)benzylamine 0-6 immunoglobulin heavy diversity 2-15 Homo sapiens 39-64 16880663-3 2006 When, in optical resolution by replacing crystallization, L-phenylalanine methyl ester hydrochloride (L-2) was used as the optically active co-solute, (2R,3S)-1.HCl was preferentially crystallized from the supersaturated racemic solution; the use of D-2 as the co-solute afforded (2S,3R)-1.HCl with an optical purity of 95%. L-Phenylalanine methyl ester hydrochloride 58-100 immunoglobulin heavy diversity 2-15 Homo sapiens 250-253 16880663-3 2006 When, in optical resolution by replacing crystallization, L-phenylalanine methyl ester hydrochloride (L-2) was used as the optically active co-solute, (2R,3S)-1.HCl was preferentially crystallized from the supersaturated racemic solution; the use of D-2 as the co-solute afforded (2S,3R)-1.HCl with an optical purity of 95%. Hydrochloric Acid 161-164 immunoglobulin heavy diversity 2-15 Homo sapiens 250-253 16885382-2 2006 Androgen [5alpha-dihydrotestosterone (DHT)] stimulation of LNCaP prostate cancer cells, which have constitutive phosphatidylinositol 3-kinase (PI3K)/Akt pathway activation due to PTEN loss, caused increased expression of cyclin D1, D2, and D3 proteins, retinoblastoma protein hyperphosphorylation, and cell cycle progression. Dihydrotestosterone 10-36 immunoglobulin heavy diversity 2-15 Homo sapiens 232-242 16497294-6 2006 Amongst the dopamine D2/serotonin 5-HT1A receptor compounds, aripiprazole acts as a partial dopamine D2S and serotonin 5-HT1A receptor agonist. Aripiprazole 61-73 immunoglobulin heavy diversity 2-15 Homo sapiens 21-49 12659902-0 2003 Fluorescence and laser properties of D2-, C2- and D3 symmetry series oligophenylenes. oligophenylenes 69-84 immunoglobulin heavy diversity 2-15 Homo sapiens 37-52 15169032-7 2004 For the antiparallel configuration with no hedgehogs between the two particles, the interaction potential is repulsive and behaves as D-2 for D less than or approximately equal 10R0, which is stronger than the dipole-dipole repulsion (approximately D-3 ) expected theoretically as an asymptotic behavior for large D. dipole 210-216 immunoglobulin heavy diversity 2-15 Homo sapiens 134-137 12763626-0 2003 Effect of D-2 amino-5-phosphonopentanoate and nifedipine on postsynaptic calcium changes associated with long-term potentiation in hippocampal CA1 area. Calcium 73-80 immunoglobulin heavy diversity 2-15 Homo sapiens 10-13 15006016-2 2004 Aripiprazole is an antipsychotic drug with high affinity for D(2)- and D(3)-receptors and the dopamine autoreceptor. Aripiprazole 0-12 immunoglobulin heavy diversity 2-15 Homo sapiens 61-85 14686220-3 2003 Unlike other antipsychotics, aripiprazole demonstrates mixed D2 and serotonin (5-HT1A) receptor agonist-antagonist activity that is hypothesized to improve schlzophrenia"s positive and negative symptoms; the drug has been referred to as a dopamine-serotonin stabilizer. Aripiprazole 29-41 immunoglobulin heavy diversity 2-15 Homo sapiens 61-95 14723347-2 2003 The absorption enhancing activity of these compounds (phytolaccosides B, D2, E, F, G and I) was determined by changes in transepithelial electrical resistance (TEER) and the transport amount of heparin disaccharide, the major repeating unit of heparin, across Caco-2 cell monolayers. heparin disaccharide 194-214 immunoglobulin heavy diversity 2-15 Homo sapiens 73-90 14723347-2 2003 The absorption enhancing activity of these compounds (phytolaccosides B, D2, E, F, G and I) was determined by changes in transepithelial electrical resistance (TEER) and the transport amount of heparin disaccharide, the major repeating unit of heparin, across Caco-2 cell monolayers. Heparin 194-201 immunoglobulin heavy diversity 2-15 Homo sapiens 73-90 10728880-6 2000 Nafadotride, UH232 and AJ76, which show a mild preference for D3 versus D2 sites, blocked the PD128,907 DS, and the modestly-selective D3 antagonist, U99194A, was partially effective. nafadotride 0-11 immunoglobulin heavy diversity 2-15 Homo sapiens 72-74 11716810-3 2001 The present study addressed these issues employing the dopaminergic agonist, quinelorane, which efficaciously stimulated G-protein activation (as assessed by [35S]GTPgammaS binding) at cloned hD2 (and hD3) receptors. quinelorane 77-88 immunoglobulin heavy diversity 2-15 Homo sapiens 192-195 11716810-3 2001 The present study addressed these issues employing the dopaminergic agonist, quinelorane, which efficaciously stimulated G-protein activation (as assessed by [35S]GTPgammaS binding) at cloned hD2 (and hD3) receptors. Sulfur-35 159-162 immunoglobulin heavy diversity 2-15 Homo sapiens 192-195 11716810-4 2001 At rat striatal membranes, dopamine stimulated [35S]GTPgammaS binding by 1.9-fold over basal, but its actions were only partially reversed by the selective D2/D3 receptor antagonist, raclopride, indicating the involvement of other receptor subtypes. Dopamine 27-35 immunoglobulin heavy diversity 2-15 Homo sapiens 156-158 11716810-4 2001 At rat striatal membranes, dopamine stimulated [35S]GTPgammaS binding by 1.9-fold over basal, but its actions were only partially reversed by the selective D2/D3 receptor antagonist, raclopride, indicating the involvement of other receptor subtypes. Raclopride 183-193 immunoglobulin heavy diversity 2-15 Homo sapiens 156-158 11716810-5 2001 In contrast, quinelorane-induced stimulation (48% of the effect of dopamine) was abolished by raclopride, and by the D2 receptor antagonist, L741,626. quinelorane 13-24 immunoglobulin heavy diversity 2-15 Homo sapiens 117-119 11716810-5 2001 In contrast, quinelorane-induced stimulation (48% of the effect of dopamine) was abolished by raclopride, and by the D2 receptor antagonist, L741,626. Dopamine 67-75 immunoglobulin heavy diversity 2-15 Homo sapiens 117-119 11716810-6 2001 Further, novel antagonists selective for D3 and D4 receptors, S33084 and S18126, respectively, blocked the actions of quinelorane at concentrations corresponding to their affinities for D2 receptors. quinelorane 118-129 immunoglobulin heavy diversity 2-15 Homo sapiens 186-188 11716810-11 2001 In conclusion, the present data indicate that, in rat striatum, the actions of quinelorane are mediated primarily by D2 receptors, and suggest that behavioural hypersensitivity to this agonist, induced by unilateral SNPC lesions, is associated with an increase in D2, but not D3 or D4, receptor-mediated G-protein activation. quinelorane 79-90 immunoglobulin heavy diversity 2-15 Homo sapiens 117-119 11716810-11 2001 In conclusion, the present data indicate that, in rat striatum, the actions of quinelorane are mediated primarily by D2 receptors, and suggest that behavioural hypersensitivity to this agonist, induced by unilateral SNPC lesions, is associated with an increase in D2, but not D3 or D4, receptor-mediated G-protein activation. quinelorane 79-90 immunoglobulin heavy diversity 2-15 Homo sapiens 264-266 11133071-2 2000 Structure-activity relationship studies have shown that h5-HT2A affinity can be attained via modifications to the tryptamine side chain and that selectivity over h5-HT2C and hD2 receptors can be controlled by suitable C-2 aryl groups. tryptamine 114-124 immunoglobulin heavy diversity 2-15 Homo sapiens 174-177 11133072-2 2000 3-(8-Phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-2-phenyl-1H-indole is a high-affinity (1.2nM), selective (>800 fold over h5-HT2C and hD2 receptors) antagonist at the h5-HT2A receptor with oral bioavailability in rats. 3-(8-phenethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-2-phenyl-1h-indole 0-63 immunoglobulin heavy diversity 2-15 Homo sapiens 133-136 11716146-1 2001 To assess the role of dopamine receptors in the genesis of dyskinesia, we have used quantitative autoradiography to determine the effect of chronic L-dopa administration on dopamine D-1 (using [3H]SCH 23390), D-2 (using [3H]spiperone) and D-3 (using [3H]7-OH-DPAT) receptor binding levels in the striatum of dyskinetic or non-dyskinetic monkeys. Levodopa 148-154 immunoglobulin heavy diversity 2-15 Homo sapiens 209-212 11716146-4 2001 Rather, a functional dissociation of D-2 receptor coupling to co-expressed enkephalin/adenosine-2a receptor activity in the striato-GPe indirect pathway may be more important in the development or expression of L-dopa-induced involuntary movements. Levodopa 211-217 immunoglobulin heavy diversity 2-15 Homo sapiens 37-40 10719223-3 2000 Compared to the long form of the D2 receptor (D2(Long)), the short form (D2(Short)) may be three times more sensitive to benzamide antipsychotic drugs. benzamide 121-130 immunoglobulin heavy diversity 2-15 Homo sapiens 46-54 10728880-6 2000 Nafadotride, UH232 and AJ76, which show a mild preference for D3 versus D2 sites, blocked the PD128,907 DS, and the modestly-selective D3 antagonist, U99194A, was partially effective. 5-methoxy-1-methyl-2-(n-propylamino)tetralin 23-27 immunoglobulin heavy diversity 2-15 Homo sapiens 72-74 10728880-6 2000 Nafadotride, UH232 and AJ76, which show a mild preference for D3 versus D2 sites, blocked the PD128,907 DS, and the modestly-selective D3 antagonist, U99194A, was partially effective. pd128 94-99 immunoglobulin heavy diversity 2-15 Homo sapiens 72-74 10728880-8 2000 However, antagonist potency (n=4) versus PD128,907 correlated better with affinity at D2 (0.89) versus D3 (0.27) sites. pd128 41-46 immunoglobulin heavy diversity 2-15 Homo sapiens 86-88 10728880-9 2000 Further, whereas the preferential D2 versus D3 antagonist, L741,626, antagonized the PD128,907 DS, the selective D3 antagonists, S11566, S14297 (its eutomer) and GR218,231 were ineffective against PD128907 and 7-OH-DPAT DS. pd128 85-90 immunoglobulin heavy diversity 2-15 Homo sapiens 34-36 10728880-9 2000 Further, whereas the preferential D2 versus D3 antagonist, L741,626, antagonized the PD128,907 DS, the selective D3 antagonists, S11566, S14297 (its eutomer) and GR218,231 were ineffective against PD128907 and 7-OH-DPAT DS. 3,4,4a,10b-tetrahydro-4-propyl-2H,5H-(1)benzopyrano(4,3-b)-1,4-oxazin-9-ol 197-205 immunoglobulin heavy diversity 2-15 Homo sapiens 34-36 10728880-9 2000 Further, whereas the preferential D2 versus D3 antagonist, L741,626, antagonized the PD128,907 DS, the selective D3 antagonists, S11566, S14297 (its eutomer) and GR218,231 were ineffective against PD128907 and 7-OH-DPAT DS. 7-hydroxy-2-N,N-dipropylaminotetralin 210-219 immunoglobulin heavy diversity 2-15 Homo sapiens 34-36 10728880-11 2000 In conclusion, under the present conditions, D2 receptors are principally implicated in the DS properties of PD128,907 and 7-OH-DPAT. ds 92-94 immunoglobulin heavy diversity 2-15 Homo sapiens 45-47 10728880-11 2000 In conclusion, under the present conditions, D2 receptors are principally implicated in the DS properties of PD128,907 and 7-OH-DPAT. pd128 109-114 immunoglobulin heavy diversity 2-15 Homo sapiens 45-47 10728880-11 2000 In conclusion, under the present conditions, D2 receptors are principally implicated in the DS properties of PD128,907 and 7-OH-DPAT. 7-hydroxy-2-N,N-dipropylaminotetralin 123-132 immunoglobulin heavy diversity 2-15 Homo sapiens 45-47 10722154-1 2000 Benzamides (3a-f) derived from 4-amino-5-chloro-2-methoxybenzoic acid and either cis or trans 1,2-diaminocyclopropane were synthesised and were evaluated in binding assays employing, bovine striatal D2 receptors, recombinant human hD2 and hD3 receptors expressed in CHO cells and rat, cortical 5-HT3 and striatal 5-HT4 receptors. Benzamides 0-10 immunoglobulin heavy diversity 2-15 Homo sapiens 199-201 10722154-1 2000 Benzamides (3a-f) derived from 4-amino-5-chloro-2-methoxybenzoic acid and either cis or trans 1,2-diaminocyclopropane were synthesised and were evaluated in binding assays employing, bovine striatal D2 receptors, recombinant human hD2 and hD3 receptors expressed in CHO cells and rat, cortical 5-HT3 and striatal 5-HT4 receptors. Benzamides 0-10 immunoglobulin heavy diversity 2-15 Homo sapiens 231-234 10360125-0 1999 Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients. Risperidone 36-47 immunoglobulin heavy diversity 2-15 Homo sapiens 70-78 10836282-1 2000 Olanzapine is an atypical antipsychotic drug which shows a high antagonistic affinity to the D1, D2 and D4 and the 5-HT2A and 5-HT2c receptors. Olanzapine 0-10 immunoglobulin heavy diversity 2-15 Homo sapiens 97-106 10530928-1 1999 Molecular modeling studies were undertaken in order to elucidate the possible dopamine D2 and serotonin 5-HT1A receptor binding modes of the enantiomers of 5-methoxy-2-[N-(2-benzamidoethyl)-N-n-propylamino]tetralin (5-OMe-BPAT, 1). 5-methoxy-2-(N-(2-benzamidoethyl)-N-n-propylamino)tetralin 156-214 immunoglobulin heavy diversity 2-15 Homo sapiens 87-119 10530928-1 1999 Molecular modeling studies were undertaken in order to elucidate the possible dopamine D2 and serotonin 5-HT1A receptor binding modes of the enantiomers of 5-methoxy-2-[N-(2-benzamidoethyl)-N-n-propylamino]tetralin (5-OMe-BPAT, 1). 5-methoxy-2-(N-(2-benzamidoethyl)-N-n-propylamino)tetralin 216-226 immunoglobulin heavy diversity 2-15 Homo sapiens 87-119 10455328-0 1999 Comparison of the functional potencies of ropinirole and other dopamine receptor agonists at human D2(long), D3 and D4.4 receptors expressed in Chinese hamster ovary cells. ropinirole 42-52 immunoglobulin heavy diversity 2-15 Homo sapiens 99-101 10455328-4 1999 All the receptor agonists tested (ropinirole, SKF-104557, SKF-97930, bromocriptine, lisuride, pergolide, pramipexole, talipexole, dopamine) increased extracellular acidification rate in Chinese hamster ovary clones expressing the human D2, D3 or D4 receptor. ropinirole 34-44 immunoglobulin heavy diversity 2-15 Homo sapiens 236-257 10434402-1 1999 In a search for novel atypical antipsychotics, the synthesis of new hexahydrocarbazoles and spiro indoles N-substituted with a 3-(dimethylamino)propyl chain is described, together with the results of an in vitro evaluation of their affinities for D2 and 5-HT2A receptors. spiro indoles n 92-107 immunoglobulin heavy diversity 2-15 Homo sapiens 247-255 10430831-5 1999 Among three dopamine receptors measured (D1, D2 and D3), the most striking changes were apparent in relation to D2. Dopamine 12-20 immunoglobulin heavy diversity 2-15 Homo sapiens 45-54 10431754-0 1999 Actions of roxindole at recombinant human dopamine D2, D3 and D4 and serotonin 5-HT1A, 5-HT1B and 5-HT1D receptors. roxindole 11-20 immunoglobulin heavy diversity 2-15 Homo sapiens 51-53 10431754-0 1999 Actions of roxindole at recombinant human dopamine D2, D3 and D4 and serotonin 5-HT1A, 5-HT1B and 5-HT1D receptors. Dopamine 42-50 immunoglobulin heavy diversity 2-15 Homo sapiens 51-53 10431754-2 1999 The present study determined its affinity and agonist efficacy at recombinant human (h) dopamine hD2, hD3 and hD4 and serotonin (5-HT) h5-HT1A, h5-HT1B and h5-HT1D receptors. Dopamine 88-96 immunoglobulin heavy diversity 2-15 Homo sapiens 97-100 10431754-3 1999 Roxindole exhibited high affinity at hD3 as well as at hD2 (short isoform) and hD4 (4-repeat isoform) receptors (pKi values 8.93, 8.55 and 8.23, respectively). roxindole 0-9 immunoglobulin heavy diversity 2-15 Homo sapiens 55-58 10431754-5 1999 In [35S]GTPgammaS binding experiments, roxindole was >20-fold more potent in stimulating [35S]GTPgammaS binding at hD3 than at hD2 or hD4 receptors (pEC50 = 9.23 vs. 7.88 and 7.69). roxindole 39-48 immunoglobulin heavy diversity 2-15 Homo sapiens 130-133 10431754-7 1999 Roxindole potently blocked dopamine-stimulated [35S]GTPgammaS binding at hD2 receptors (pkappaB = 9.05). roxindole 0-9 immunoglobulin heavy diversity 2-15 Homo sapiens 73-76 10431754-7 1999 Roxindole potently blocked dopamine-stimulated [35S]GTPgammaS binding at hD2 receptors (pkappaB = 9.05). Dopamine 27-35 immunoglobulin heavy diversity 2-15 Homo sapiens 73-76 10431754-7 1999 Roxindole potently blocked dopamine-stimulated [35S]GTPgammaS binding at hD2 receptors (pkappaB = 9.05). Sulfur-35 48-51 immunoglobulin heavy diversity 2-15 Homo sapiens 73-76 10431754-8 1999 In comparison, the dopamine receptor agonist, (-)quinpirole, acted as a partial agonist at hD3 and hD4 sites (Emax = 67.4% and 66.3%, respectively) but surpassed the efficacy of dopamine at hD2 receptors (Emax = 132%). Quinpirole 49-59 immunoglobulin heavy diversity 2-15 Homo sapiens 190-193 10431754-8 1999 In comparison, the dopamine receptor agonist, (-)quinpirole, acted as a partial agonist at hD3 and hD4 sites (Emax = 67.4% and 66.3%, respectively) but surpassed the efficacy of dopamine at hD2 receptors (Emax = 132%). Dopamine 19-27 immunoglobulin heavy diversity 2-15 Homo sapiens 190-193 10431754-12 1999 The present data suggest that roxindole activates mainly D3 vs. D2 or D4 receptors and 5-HT1A vs. 5-HT1B or 5-HT1D receptors. roxindole 30-39 immunoglobulin heavy diversity 2-15 Homo sapiens 64-66 10211140-3 1999 In vivo studies showed that olanzapine had potent activity at D2 and 5-HT2A receptors, but much less activity at D1 and muscarinic receptors, and that it inhibited dopaminergic neurons in the A10 but not the A9 tract, suggesting that this agent will not cause extrapyramidal side-effects (EPS). Olanzapine 28-38 immunoglobulin heavy diversity 2-15 Homo sapiens 62-70 10455328-4 1999 All the receptor agonists tested (ropinirole, SKF-104557, SKF-97930, bromocriptine, lisuride, pergolide, pramipexole, talipexole, dopamine) increased extracellular acidification rate in Chinese hamster ovary clones expressing the human D2, D3 or D4 receptor. Dopamine 130-138 immunoglobulin heavy diversity 2-15 Homo sapiens 236-257 10455328-5 1999 The pEC50s of ropinirole at hD2, hD3 and hD4 receptors were 7.4, 8.4 and 6.8, respectively. ropinirole 14-24 immunoglobulin heavy diversity 2-15 Homo sapiens 28-31 10455328-6 1999 Ropinirole is therefore at least 10 fold selective for the human dopamine D3 receptor over the other D2 receptor family members. ropinirole 0-10 immunoglobulin heavy diversity 2-15 Homo sapiens 101-103 10455328-8 1999 At the hD2 and hD3 dopamine receptors all the compounds tested were full agonists as compared to quinpirole. Quinpirole 97-107 immunoglobulin heavy diversity 2-15 Homo sapiens 7-10 10455328-16 1999 The results show that ropinirole is a full agonist at human D2, D3 and D4 dopamine receptors. ropinirole 22-32 immunoglobulin heavy diversity 2-15 Homo sapiens 60-62 10234579-9 1999 Testosterone concentrations were markedly suppressed on both D2 and D3 (-95%, p < 0.006), whereas there were no detectable changes in growth hormone and insulin-like growth factor-1 concentrations. Testosterone 0-12 immunoglobulin heavy diversity 2-15 Homo sapiens 61-70 10051542-9 1999 Antibodies against Galphai/alphao reduced dopamine-induced G protein activation at both CHO-hD3 and -hD2 membranes, whereas GalphaS antibodies had no effect at either site. Dopamine 42-50 immunoglobulin heavy diversity 2-15 Homo sapiens 101-104 9765336-3 1998 In contrast, raclopride displayed low affinity at hD4 (> 3000 nM) vs. hD2 (1.1 nM) and hD3 receptors (1.4 nM). Raclopride 13-23 immunoglobulin heavy diversity 2-15 Homo sapiens 73-76 9765336-5 1998 In contrast, raclopride inhibited stimulation of [35S]-GTPgammaS binding at hD2 sites by DA with a Kb of 1.4 nM, whereas S 18126 (> 1000 nM) and L 745,870 (> 1000 nM) were inactive. Raclopride 13-23 immunoglobulin heavy diversity 2-15 Homo sapiens 76-79 9765336-5 1998 In contrast, raclopride inhibited stimulation of [35S]-GTPgammaS binding at hD2 sites by DA with a Kb of 1.4 nM, whereas S 18126 (> 1000 nM) and L 745,870 (> 1000 nM) were inactive. Sulfur-35 50-53 immunoglobulin heavy diversity 2-15 Homo sapiens 76-79 9765337-6 1998 The rank order of preference (Ki ratio, D2:D3) for D3 receptors (labeled by [3H]-PD 128,907) vs. D2 sites (labeled by [125I]-iodosulpride) was (+)-S 14297 (61) approximately GR 103,691 (60) > U 99194 (14) > nafadotride (9) approximately (+)-UH 232 (8) approximately (+)-AJ 76 (6) > haloperidol (0.2). iodosulpride 125-137 immunoglobulin heavy diversity 2-15 Homo sapiens 97-99 9732398-12 1998 Clozapine was, similarly, weakly active in these models, whereas haloperidol, in line with its higher affinity at D2 (and D3) receptors, was potently active. Haloperidol 65-76 immunoglobulin heavy diversity 2-15 Homo sapiens 114-116 9513604-2 1998 The structural contributions to D2/D3 and 5-HT1A receptor binding of the aminopyrimidine, cycloalkyl, and phenylpiperazine portions of the molecule were examined. 2-aminopyrimidine 73-88 immunoglobulin heavy diversity 2-15 Homo sapiens 32-48 9871765-4 1998 Furthermore, in comparison to BMY 7378, cystazosin (3) displays a much better specificity profile since it has lower affinity for D2 and 5-HT1A receptors. cystazosin 40-50 immunoglobulin heavy diversity 2-15 Homo sapiens 130-153 9690965-5 1998 The novel antipsychotics risperidone and olanzapine induced high occupancy of both D2 and 5-HT2A receptors at suggested standard doses. Risperidone 25-36 immunoglobulin heavy diversity 2-15 Homo sapiens 83-91 9690965-5 1998 The novel antipsychotics risperidone and olanzapine induced high occupancy of both D2 and 5-HT2A receptors at suggested standard doses. Olanzapine 41-51 immunoglobulin heavy diversity 2-15 Homo sapiens 83-91 9760039-8 1998 Clozapine and several putatively "atypical" antipsychotic agents, including ziprasidone, quetiapine and tiospirone, exhibited partial agonist activity and marked affinity at h5-HT1A receptors, similar to their affinity at hD2 dopamine receptors. Clozapine 0-9 immunoglobulin heavy diversity 2-15 Homo sapiens 222-225 9760039-8 1998 Clozapine and several putatively "atypical" antipsychotic agents, including ziprasidone, quetiapine and tiospirone, exhibited partial agonist activity and marked affinity at h5-HT1A receptors, similar to their affinity at hD2 dopamine receptors. tiospirone 104-114 immunoglobulin heavy diversity 2-15 Homo sapiens 222-225 9513604-2 1998 The structural contributions to D2/D3 and 5-HT1A receptor binding of the aminopyrimidine, cycloalkyl, and phenylpiperazine portions of the molecule were examined. cycloalkyl 90-100 immunoglobulin heavy diversity 2-15 Homo sapiens 32-48 9513604-2 1998 The structural contributions to D2/D3 and 5-HT1A receptor binding of the aminopyrimidine, cycloalkyl, and phenylpiperazine portions of the molecule were examined. phenylpiperazine 106-122 immunoglobulin heavy diversity 2-15 Homo sapiens 32-48 9456299-4 1998 From the mass spectrometry and 1H-NMR data, it is concluded that D-2 and D-3 are formed from beclomethasone and beclomethasone 21-monopropionate, respectively, with the loss of hydrogen chloride and the formation of a 9,11-epoxide. Hydrogen 31-33 immunoglobulin heavy diversity 2-15 Homo sapiens 65-76 9456299-4 1998 From the mass spectrometry and 1H-NMR data, it is concluded that D-2 and D-3 are formed from beclomethasone and beclomethasone 21-monopropionate, respectively, with the loss of hydrogen chloride and the formation of a 9,11-epoxide. Beclomethasone 93-107 immunoglobulin heavy diversity 2-15 Homo sapiens 65-76 9456299-4 1998 From the mass spectrometry and 1H-NMR data, it is concluded that D-2 and D-3 are formed from beclomethasone and beclomethasone 21-monopropionate, respectively, with the loss of hydrogen chloride and the formation of a 9,11-epoxide. Beclomethasone 21-Propionate 112-144 immunoglobulin heavy diversity 2-15 Homo sapiens 65-76 9456299-4 1998 From the mass spectrometry and 1H-NMR data, it is concluded that D-2 and D-3 are formed from beclomethasone and beclomethasone 21-monopropionate, respectively, with the loss of hydrogen chloride and the formation of a 9,11-epoxide. Hydrochloric Acid 177-194 immunoglobulin heavy diversity 2-15 Homo sapiens 65-76 9456299-4 1998 From the mass spectrometry and 1H-NMR data, it is concluded that D-2 and D-3 are formed from beclomethasone and beclomethasone 21-monopropionate, respectively, with the loss of hydrogen chloride and the formation of a 9,11-epoxide. 9,11-epoxide 218-230 immunoglobulin heavy diversity 2-15 Homo sapiens 65-76 9502100-2 1998 The orally bioavailable 7-azaindole compound 11 has nanomolar affinity at the hD4 receptor with > 1000-fold selectivity over the hD2 receptor. 7-azaindole dimer 24-35 immunoglobulin heavy diversity 2-15 Homo sapiens 132-135